Sakaue et al

1 Tissue-specific enhancer-gene maps from multimodal single-cell data

Saori Sakaue^{1,2,3}, Kathryn Weinand^{1,2,3,4}, Shakson Isaac^{1,2,3,4}, Kushal K. Dey^{3,5}, Karthik

2 identify causal disease alleles

3

- 5 Jagadeesh^{3,5}, Masahiro Kanai^{3,6,7,8}, Gerald F. M. Watts⁹, Zhu Zhu⁹, Accelerating Medicines 6 Partnership® RA/SLE Program and Network, Michael B. Brenner⁹, Andrew McDavid¹⁰, Laura T. 7 Donlin^{11,12}. Kevin Wei⁹. Alkes L. Price^{3,5,13}. Soumva Ravchaudhuri^{1,2,3,4,*} 8 1. Center for Data Sciences, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 9 USA 10 2. Divisions of Genetics and Rheumatology, Department of Medicine, Brigham and Women's 11 Hospital, Harvard Medical School, Boston, MA, USA 12 Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, 3. 13 MA. USA 14 4. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA 15 Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA 5. 16 Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA 6. 17 7. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, 18 USA 19 8. Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, 20 USA 21 9. Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and 22 Women's Hospital and Harvard Medical School, Boston, MA, USA 23 Department of Biostatistics and Computational Biology, University of Rochester Medical Center, 10. 24 Rochester, NY, USA 25 11. Hospital for Special Surgery, New York, NY, USA 26 12. Weill Cornell Medicine, New York, NY, USA 27 13. Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA 28 29 *Address correspondence to: 30 Soumya Raychaudhuri
- 31 77 Avenue Louis Pasteur, Harvard New Research Building, Suite 250D
- 32 Boston, MA 02446, USA.
- 33 soumya@broadinstitute.org
- 34 617-525-4484 (tel); 617-525-4488 (fax)
- 35

Sakaue et al

36 Abstract

37 Translating genome-wide association study (GWAS) loci into causal variants and genes requires 38 accurate cell-type-specific enhancer-gene maps from disease-relevant tissues. Building 39 enhancer-gene maps is essential but challenging with current experimental methods in primary 40 human tissues. We developed a new non-parametric statistical method, SCENT (Single-Cell 41 ENhancer Target gene mapping) which models association between enhancer chromatin 42 accessibility and gene expression in single-cell multimodal RNA-seq and ATAC-seq data. We 43 applied SCENT to 9 multimodal datasets including > 120,000 single cells and created 23 celltype-specific enhancer-gene maps. These maps were highly enriched for causal variants in 44 45 eQTLs and GWAS for 1,143 diseases and traits. We identified likely causal genes for both 46 common and rare diseases. In addition, we were able to link somatic mutation hotspots to target 47 genes. We demonstrate that application of SCENT to multimodal data from disease-relevant 48 human tissue enables the scalable construction of accurate cell-type-specific enhancer-gene 49 maps, essential for defining non-coding variant function.

Sakaue et al

51 Main

52 Introduction

Genome-wide association studies (GWAS) have comprehensively mapped loci for human diseases^{1–4}. These loci harbor untapped insights about causal mechanisms that can point to novel therapeutics^{2,5}. However, only rarely are we able to define causal variants or their target genes. Of the hundreds of associated variants in a single locus, only one or a few may be causal; others are associated since they tag causal variants^{2,6,7}. Moreover, causal genes are also challenging to determine, since causal variants lie in non-coding regions in 90% of the time^{8–10}, may regulate distant genes^{11–13}, and may employ context-specific regulatory mechanisms^{14–17}.

60 To define causal variants and genes, previous studies have used both statistical and experimental approaches. Statistical fine-mapping¹⁸⁻²³ can narrow the set of candidate causal 61 62 variants, and is more effective when GWAS includes diverse ancestral backgrounds with 63 different allele frequencies and linkage disequilibrium structures (LD)²⁴⁻²⁸. However, these approaches alone are seldom able to identify true causal variants with confidence^{7,23,29–32}. To 64 65 define causal genes, previous studies have built enhancer-gene maps, that can be used to 66 prioritize causal variants in enhancers and link causal variants to genes they regulate. These 67 maps often require large-scale epigenetic and transcriptomic atlases (e.g., Roadmap³³, BLUEPRINT³⁴, and ENCODE³⁵). The enhancer-gene maps have been built from these atlases 68 69 by correlating epigenetic activity (i.e., enhancer activity; e.g., histone mark ChIP-seg and bulk ATAC-seq) with gene expression (e.g., RNA-seq)^{36,37}, by combining epigenetic activity and 70 71 probability of physical contact with the gene^{38,39}, or by integrating multiple linking strategies to 72 create composite scores ⁴⁰. However, current methods largely use bulk tissues or cell lines. Bulk

Sakaue et al

data potentially (i) cannot be easily applied to rare cell populations (ii) obscures the cell-typespecific nature of gene regulation and (iii) requires hundreds of experimentally characterized samples, necessitating consortium-level efforts. While perturbation experiments (e.g., CRISPR interference⁴¹ or base editing⁴²) can point to causal links between enhancers and genes, they are difficult to scale because they require the cell- or tissue-type specific experimental protocols⁴³.

Advances in single-cell technologies offer new opportunities for building cell-type specific 79 80 enhancer-gene maps. Multimodal protocols now enable joint capture of epigenetic activity by ATAC-seq alongside early transcriptional activity with nuclear RNA-seq⁴⁴⁻⁴⁸. These methods 81 82 are easily applied at scale to cells in human primary tissues without disaggregation, enabling 83 query of many samples from disease-relevant tissues. If we establish accurate links between open chromatin enhancers and genes in single cells, statistical power should exceed bulk-tissue-84 85 based methods since each observation is at a cell-level resolution. However, the sparse and 86 non-parametric nature of RNA-seg and ATAC-seg in single-cell experiments makes confident 87 identification of these links challenging. To date, most methods use linear regression models to link enhancers and genes (e.g., ArchR⁴⁹ and Signac⁵⁰) despite these features or only utilize co-88 89 accessibility of regulatory regions from ATAC-seg but not gene expression from sc-RNA-seg (e.g., Cicero⁵¹). These previous methods have not generally demonstrated efficacy in practice 90 91 for causal variant fine-mapping in complex traits.

In this context, we developed <u>Single-Cell Enhancer Target gene mapping</u> (SCENT), to
 accurately map enhancer-gene pairs where an enhancer's activity (i.e. peak accessibility) is

Sakaue et al

94	associated with gene expression across individual single cells. We use Poisson regression and
95	non-parametric bootstrapping ⁵² to account for the sparsity and non-parametric distributions. We
96	predicted that peaks with gene associations are more likely to be functionally important. We
97	apply SCENT to 9 multimodal datasets to build 23 cell-type specific enhancer-gene maps. We
98	show that SCENT enhancers are highly enriched in statistically fine-mapped likely causal
99	variants for eQTL and GWAS. We use SCENT enhancer-gene map to define causal variants,
100	genes, and cell types in common and rare disease loci and somatic mutation hotspots, which
101	has not been previously demonstrated by conventional enhancer-gene mapping based on bulk-
102	tissues.

- 103
- 104 **Results**

105 Overview of SCENT

106 To identify (1) active *cis*-regulatory regions and (2) their target genes (3) in a given cell type, we 107 leveraged single-cell multimodal datasets. SCENT accurately identifies significant association 108 between chromatin accessibility of regulatory regions (i.e., peaks) from ATAC-seq and gene 109 expression from RNA-seq across individual single cells (Figure 1a). Those associations can be 110 used for prioritizing (1) likely causal variants if they are in regulatory regions that are associated 111 with gene expression, (2) likely causal genes if they are associated with the identified regulatory 112 region and (3) the critical cell types based on which map the association is identified in. We 113 assessed whether binarized chromatin accessibility in an ATAC peak is associated with gene 114 expression counts in *cis* (< 500kb from gene body), testing one peak-gene pair at a time in each

Sakaue et al

cell type (see Methods). We tested each cell type separately to capture cell-type-specific gene
regulation and to avoid spurious peak-gene associations due to gene co-regulation across cell
types.

Since both RNA-seq and ATAC-seq data are generally sparse^{50,53–56}, we used Poisson regression since it was a simple model that has been used effectively for sc-RNA-seq analysis^{54,57}:

121

$$E_i \sim Poisson(\lambda_i)$$

122
$$log(\lambda_i) = \beta_0 + \beta_{peak} X_{peak} + \beta_{\% mito} X_{\% mito} + \beta_{nUMI} X_{nUMI} + \beta_{batch} X_{batch}$$

where E_i is the observed expression count of *i*th gene, and λ_i is the expected count under Poisson distribution. β_{peak} indicates the effect of chromatin accessibility of a peak on *i* th gene expression (see **Methods**) and reflects the strength of the regulatory effect and sign (i.e., enhancing vs. silencing effect). We accounted for donor or batch effects (X_{batch}) and cell-level technical factors such as percentage of mitochondrial reads ($X_{%mito}$).

128 However, gene expression counts are highly variable across genes (Figure 1b; 129 **Supplementary Figure 1a**), and Poisson regression might be suboptimal for highly expressed 130 and dispersed genes. Consequently, we observed inflated statistics when we permuted cell 131 barcodes to disrupt association between ATAC and RNA profiles (**Supplementary Figure 1b**). 132 Common analytical statistical models (e.g., linear, negative binomial and Poisson regression) all 133 demonstrated inflated statistics (Supplementary Figure 1c-e). Therefore, to accurately 134 estimate the error and significance of β_{peak} , we implemented non-parametric bootstrapping 135 framework. Briefly, we resampled cells with replacement from the full data and re-estimated

Sakaue et al

136 β'_{peak} up to 50,000 times. We compared this empirical distribution of β'_{peak} against null 137 hypothesis ($\beta'_{peak} = 0$) to derive the significance of β_{peak} (i.e., two-sided bootstrapping-based 138 *P* value; see **Methods, Supplementary Figure 2**). The Poisson regression followed by 139 bootstrapping resulted in well-calibrated statistics with appropriate type I error (**Supplementary** 140 **Figure 1f**).

Sakaue et al

141



142 Figure 1. Schematic overview of SCENT and SCENT enhancer-gene pairs across 9 singlecell multimodal datasets. a. SCENT identifies (1) active cis-regulatory regions and (2) their 143 144 target genes in (3) a specific cell type. Those SCENT results can be used to define likely causal variants, genes, and cell types for GWAS loci. b. SCENT models association between chromatin 145 146 accessibility from ATAC-seg and gene expression from RNA-seg across individual cells in a 147 given cell type. c. 9 single-cell datasets on which we applied SCENT to create 23 cell-type-148 specific enhancer-gene map. The cells in each dataset are described in UMAP embeddings from 149 RNA-seg and colored by cell types.

Sakaue et al

150 Discovery of cell-type-specific SCENT enhancer-gene links

151 We obtained nine single-cell multimodal datasets from diverse human tissues representing 13 152 cell-types (immune-related, hematopoietic, neuronal, and pituitary). Since we are interested in 153 autoimmune diseases, we newly generated an inflammatory tissue dataset by obtaining inflamed 154 synovial tissues from ten rheumatoid arthritis (RA) and two osteoarthritis (OA) patients (arthritis-155 tissue dataset: $n_{donor} = 12$). Applying stringent QC to these multimodal data, we obtained information on 30,893 cells (see Methods). In addition, we obtained eight public datasets with 156 157 129,672 cells. In total we had data from 160,565 cells^{46,58–62}. We analyzed 16,621 genes and 158 1,193,842 open chromatin peaks in *cis* after QC (4,753,521 peak-gene pairs, 28 median peaks 159 per gene; Figure 1c, Supplementary Figure 3, Supplementary Table 1). After clustering cells 160 and cell type annotation, we applied SCENT individually to each of the cell types with $n_{cells} > 500$ 161 to construct 23 enhancer-gene maps. SCENT identified 87,648 cell-type-specific peak-gene 162 links (false discovery rate (FDR) < 10%, Figure 2a, Supplementary Figure 4). Each gene had 163 variable number of associated peaks in *cis* (from 0 to 97, mean = 4.13, **Supplementary Figure** 164 5a).

To assess replicability of SCENT peak-gene links, we compared the effects from the arthritis-tissue dataset (discovery; which had the largest number of significant peak-gene pairs) with those from other datasets in the same cell-type (replication) in B cells, T/NK cells and myeloid cells (**Supplementary Table 2a**). Despite different tissue contexts, we confirmed high directional concordance of the effect of chromatin accessibility on gene expression for peakgene pairs significant in both datasets (mean Pearson r = 0.62 of effect sizes, 99% mean

Sakaue et al

171	concordance across all the datasets: Supplementary Figure 5b). For comparison, we tested
172	two popular linear parametric single-cell multimodal methods that are already published, namely
173	ArchR ⁵⁶ or Signac ⁵⁰ . Using arthritis-tissue dataset as a discovery and public PBMC as a
174	replication, we noted lower directional concordance and effect correlation in these methods than
175	in SCENT (mean Pearson's $r = 0.31$, 62% mean directional concordance in ArchR and $r = 0.24$,
176	98% mean directional concordance in Signac; Supplementary Table 2b and c). These results
177	argue that SCENT can more reproducibly detect enhancer-gene links compared with previous
178	parametric methods for single-cell multimodal data.

Sakaue et al

180



Figure 2. SCENT identified functionally active and evolutionary conserved *cis*-regulatory regions from single-cell multimodal data.

a. The number of significant gene-peak pairs discovered by SCENT with FDR < 10%. Each dot 183 represents the number of significant gene-peak pairs in a given cell type in a dataset (y-axis) as 184 185 a function of the number of cells in each cell type in a dataset (x-axis), colored by the dataset. 186 **b.** The effect size (beta) of chromatin accessibility on the gene expression from Poisson 187 regression (y-axis). Each dot is a significant gene-peak pair and plotted against the distance 188 between the peak and the transcription start site (TSS) of the gene, colored as a density plot. c. 189 The mean effect size (beta) of chromatin accessibility on the gene expression in arthritis-tissue 190 dataset within each bin of TSS distance. Left; all significant gene-peak links. Right; SCENT 191 peaks within enhancers identified using chromHMM in immune-related tissues. d. Mean 192 phastCons score difference (A phastCons score) between each annotated region and all cis-193 regulatory non-coding regions. We show the Δ phastCons score for exonic regions (purple) as 194 a reference, and for SCENT (green) and all cis-ATAC peaks (yellow) enhancers in each 195 multimodal dataset.

Sakaue et al

196	To assess if SCENT peaks (i.e., cis-regulatory regions) were functional, we examined if
197	(1) they co-localized with conventional cis-regulatory annotation, (2) their effect on expression
198	was greater for closer peak-gene pairs, (3) they had high sequence conservation, and (4) peak-
199	gene connections were more likely to be validated experimentally.
200	First, we tested the overlap of SCENT peaks with an ENCODE cCRE ⁶³ , a conventional
201	cis-regulatory annotation by bulk epigenomic datasets. We observed that 98.0% of the SCENT

202 peaks overlapped with ENCODE cCRE on average, compared to 23.3% of random *cis*-regions

203 matched for size and 89.0% of non-SCENT peaks (**Supplementary Figure 5c**).

204 Second, we examined the strength of enhance-gene links, hypothesizing that stronger 205 links would be more proximal to the transcription start site (TSS) of target genes. The regression coefficient β_{peak} (the effect size of peak accessibility on gene expression) became larger and 206 207 more positive as the SCENT peaks got closer to the TSS (Figure 2b and Figure 2c, left panel), 208 consistent with previous observations^{56,64}. We annotated SCENT peaks with 18-state 209 chromHMM results from 41 immune-related samples in ENCODE consortium³⁷. When we subset peaks to those within enhancer annotations, we observed a clearer decay in β_{peak} as a function 210 211 of TSS distance (Figure 2c, right panel).

Third, we assessed whether SCENT peaks had higher sequence conversation across species, quantified as phastCons score⁶⁶, which should indicate functional importance; the evolutionary conserved regulatory regions are known to be enriched for complex trait heritability⁶⁵. As expected, exonic regions were much more evolutionary conserved than all noncoding *cis*-region (mean Δ phastCons score = 0.38, paired t-test *P* < 10⁻³²³; **Figure 2d**, purple).

Sakaue et al

217	The SCENT regulatory regions were also conserved relative to non-coding <i>cis</i> -regions (mean Δ
218	phastCons score = 0.13, paired t-test $P = 4.2 \times 10^{-42}$ in arthritis-tissue dataset; Figure 2d , green).
219	In contrast, the Δ phastCons score between all <i>cis</i> -ATAC peaks and all non-coding <i>cis</i> -region
220	was more modest (mean Δ phastCons score = 0.092, paired t-test P = 8.7 x10 ⁻²⁷ in arthritis-
221	tissue dataset; Figure 2d, yellow). To test if the higher conservation in SCENT peaks were
222	driven by their proximity to TSS (Supplementary Figure 6a), we matched each of the SCENT
223	peak-gene pairs to one non-SCENT peak-gene pair that had the most similar TSS distance
224	(Supplementary Figure 6b). We assessed Δ phastCons score between SCENT peaks and
225	non-SCENT peaks with matching peaks on TSS distance. SCENT peaks had significantly higher
226	conservation scores than the non-SCENT peaks with the matched TSS distance (mean Δ
227	phastCons score = 0.034, $P = 4.7 \times 10^{-4}$ in arthritis-tissue dataset; Supplementary Figure 5d ;
228	see Methods). The higher sequence conservation suggested the functional importance of
229	SCENT regulatory regions not solely driven by TSS proximity.

Finally, we tested whether the target genes from SCENT were enriched for experimentally confirmed enhancer-gene links. We used Nasser et al.³⁹ CRISPR-Flow FISH results which included 278 positive enhancer-gene connections and 5,470 negative connections. The SCENT peaks were >4-fold enriched relative to non-SCENT peaks for positive connections (Fisher's exact OR=4.5X, P=1.8x10⁻⁹ in arthritis-tissue dataset and 4.5X, P=1.0x10⁻⁸ in public PBMC dataset; **Methods, Supplementary Table 3**).

We anticipate that the genes with the largest number of SCENT peaks are likely to be the most constraint and least tolerant to loss of function mutations. The genes with the most SCENT

Sakaue et al

238	peaks included FOSB ($n = 97$), JUNB ($n = 95$), and RUNX1 ($n = 77$), critical and highly conserved
239	transcription factors. We used mutational constraint metrics based on the absence of deleterious
240	variants within human populations (i.e., the probability of being loss-of-function intolerant (pLI) ⁶⁷
241	and the loss-of-function observed/expected upper bound fraction (LOEUF)68). The normalized
242	number of SCENT peaks per gene is strongly associated with mean constraint score for the
243	gene (beta=0.37, P=4.9x10 ⁻⁹⁰ for pLI where higher score indicates more constraint, and beta=-
244	0.35, P =-0.35x10 ⁻¹⁰⁶ for LOEUF where lower score indicates more constraint; Supplementary
245	Figure 7a and 7b, respectively). Previously, genes with many regulatory regions from bulk-
246	epigenomic data had been shown to be enriched for loss-of-function intolerant genes ⁶⁹ . We
247	replicated the same trend in the single-cell multimodal datasets and SCENT.

248

249 Enrichment of eQTL putative causal variants in SCENT peaks

250 We examined whether the SCENT peaks are likely to harbor statistically fine-mapped putative 251 causal variants for expression quantitative loci (eQTL). We used tissue-specific eQTL finemapping results from GTEx across 49 tissues⁷⁰ and defined any variants with posterior inclusion 252 253 probability (PIP) > 0.2 as putative causal variants. We computed enrichment statistics within 254 ATAC peaks or SCENT peaks (see **Methods**). Unsurprisingly, all the accessible regions defined 255 by ATAC-seq in *cis*-regions were modestly enriched in fine-mapped variants by 2.7X (yellow, 256 Figure 3a). However, SCENT peaks were more strikingly enriched in fine-mapped variants by 257 9.6X on average across all datasets (green, Figure 3a). Using more stringent PIP threshold

Sakaue et al

258 cutoffs (0.5 and 0.7) to define putative causal variants resulted in even stronger enrichments

259 (Supplementary Figure 8).

- 260 Since many SCENT peaks are close to TSS regions, we again considered whether this
- 261 enrichment might be driven by TSS proximity (**Supplementary Figure 6a**). To test this, we
- 262 compared the fine-mapped variant enrichment between SCENT and non-SCENT peak-gene
- 263 pairs with matched TSS distance (**Supplementary Figure 6b**). The SCENT peaks consistently
- had higher enrichment in all analyzed datasets (Supplementary Figure 9a) than TSS-
- 265 distance-matched non-SCENT peaks (e.g., 12.3X in SCENT vs. 9.64X in distance-matched
- 266 non-SCENT in arthritis-tissue dataset). This suggests that SCENT has additional information in
- 267 identifying functional *cis*-regulatory regions beyond TSS distance.

Sakaue et al



268

Figure 3. SCENT enhancers are enriched in putative causal variants of eQTL and GWAS. 269 270 a. The mean causal variant enrichment for eQTL within SCENT peaks or all ATAC-seq peaks in each of the 9 single-cell datasets. The bars indicate 95% confidence intervals by bootstrapping 271 272 genes. b. Comparison of the mean causal variant enrichment for eQTL (y-axis) between SCENT (green), ArchR (pink), and Signac (purple) as a function of the number of significant peak-gene 273 274 pairs at each threshold of significance. The bars indicate 95% confidence intervals by 275 bootstrapping genes. The ArchR results with > 100,000 peak-gene linkages are omitted, and full 276 results are in Supplementary Figure 9b. c and d. The mean causal variant enrichment for 277 GWAS within SCENT enhancers (green), all cis-ATAC peaks (yellow), ENCODE cCREs (pink), 278 EpiMap enhancers across all groups (red) and ABC enhancers across all samples (blue). GWAS 279 results were based on FinnGen (c) and UK Biobank (d). The bars indicate 95% confidence 280 intervals by bootstrapping traits. e. The mean causal variant enrichment for FinnGen GWAS 281 within intersection of SCENT enhancers and caQTL enhancers at each threshold of significance. 282 The bars indicate 95% confidence intervals by bootstrapping traits.

Sakaue et al

283 We next compared the enrichment for eQTL putative causal variants in SCENT peaks to 284 peaks identified by the two published linear parametric methods using single-cell multimodal 285 data, ArchR⁵⁶ and Signac⁵⁰ using the same dataset. ArchR and Signac peaks had substantially 286 lower causal variant enrichment for eQTL (1.4X and 9.3X, respectively) compared to SCENT peaks (74.1X) with FDR<0.10. We were concerned that this performance differences may reflect 287 288 variable recall: that is SCENT may be more restrictive and calling fewer peaks. By varying the 289 thresholds to define significant peak-gene associations (see **Methods**), we called the number of 290 peak-gene pairs with difference levels of stringency and tested causal variant enrichment (i.e., 291 recall-precision tradeoff; Figure 3b and Supplementary Figure 9b). SCENT peaks consistently 292 demonstrated higher causal variant enrichment (i.e., precision) than ArchR and Signac peaks 293 across different recall values.

We also tested Cicero⁵¹, which is a published linear parametric method for detecting promoter-enhancer co-accessibility from ATAC-seq data alone. We confirmed that SCENT peaks demonstrated higher causal variant enrichment than Cicero using the same dataset but only with ATAC-seq side (**Supplementary Figure 9c**; see **Methods**).

We assessed whether the Poisson regression or the bootstrapping in SCENT was driving its performance over other linear parametric methods. We benchmarked causal variant enrichment in SCENT peaks against peaks identified with only Poisson regression but without non-parametric bootstrapping (see **Methods**). As previously mentioned, we already observed false positive associations in the simulated null datasets in the Poisson-only strategy (**Supplementary Figure 1c**). Indeed, we observed substantially lower causal variant enrichment

Sakaue et al

at a given recall compared to SCENT (14.4X in Poisson only vs. 74.1X in SCENT at the same
FDR<0.10), albeit slightly higher than the linear methods ArchR and Signac (Supplementary
Figure 9c). This underscored the importance of accounting for both (1) sparsity by Poisson
regression and (2) highly variable gene count distribution by non-parametric bootstrapping to
achieve high precision in SCENT.

309 SCENT can detect *cis*-regulatory regions in a cell-type-specific manner. We created cell-310 type-specific enhancer-gene maps in four major cell types with > 5,000 cells across datasets; 311 for each cell type we took the union of SCENT enhancers across datasets. The cell-type-specific 312 SCENT enhancers (e.g., SCENT B cell peaks) were most enriched in putative causal eQTL 313 variants within relevant samples in GTEx (e.g., EBV-transformed lymphocytes; **Supplementary** 314 **Figure 9d**).

These results suggest that SCENT can prioritize regulatory elements harboring putative causal eQTL variants in a cell-type-specific manner, with higher precision than the previous single-cell methods.

318

319 Enrichment of likely causal variants for GWAS in SCENT enhancers

SCENT applied for multimodal data from disease-relevant tissues can build disease-specific enhancer-gene maps. We sought to examine whether SCENT peaks can be used for the more difficult task of prioritizing disease causal variants. We obtained candidate causal variants for diseases and traits from fine-mapping results of GWASs in two large-scale biobanks (PIP>0.2; FinnGen⁷¹ [1,046 disease traits] and UK Biobank⁷² [35 binary traits and 59 quantitative traits])²⁸.

Sakaue et al

325 We computed enrichment statistics for causal GWAS variants within SCENT enhancers (both 326 cell-type-specific tracks and aggregated tracks across cell types; see **Methods**). The SCENT 327 enhancers were strikingly enriched in causal GWAS variants in FinnGen (31.6X on average; 328 1046 traits; Figure 3c and Supplementary Figure 10a) and UK Biobank (73.2X on average; 94 329 traits; Figure 3d and Supplementary Figure 10b). This enrichment was again much larger than 330 all cis-ATAC peaks (12.8X in FinnGen and 38.8X in UK Biobank). Moreover, the target genes of 331 the likely causal variants for autoimmune diseases (AID) identified by SCENT peaks in immune-332 related cell types had higher fraction (10.8%) of know genes implicated in Mendelian disorders 333 of immune dysregulation ($n_{gene} = 550$)^{73,74} than SCENT peaks in fibroblast (3.8%; 334 Supplementary Figure 10c).

335 We compared SCENT to alternative genome annotations and enhancer-gene maps from 336 bulk tissues. Causal variant enrichment in SCENT was much higher than the conventional bulk-337 based annotations such as ENCODE cCREs (13.9X in FinnGen and 46.5X in UK Biobank), ABC (16.3X in FinnGen and 53.3X in UK Biobank) and EpiMap (12.9X in FinnGen and 40.6X in UK 338 339 Biobank; Figure 3c and 3d [aggregated tracks], Supplementary Figure 10a and 10b [cell-type-340 specific tracks]). We again assessed recall and precision tradeoffs by varying thresholds for 341 defining significant peak-gene linkages. We constructed SCENT from 9 datasets and 23 cell 342 types with only 28 samples, substantially less than the 833 samples and tissues used to 343 construct EpiMap and 131 samples and cell lines for the ABC model. Despite the smaller data 344 set, SCENT peaks consistently demonstrated higher precision (i.e., enrichment of causal GWAS 345 variants) at a given recall (i.e., a similar number of identified peak-gene linkages) than ABC

Sakaue et al

model and EpiMap (Supplementary Figure 11a). A more stringent PIP threshold (0.5 and 0.7)
for putative causal variants increased the enrichment while maintaining the higher enrichment in
SCENT than bulk methods (Supplementary Figure 11b). The target genes for AID by SCENT
in immune-related cell types had higher fraction (10.8%) of known Mendelian genes of immune
dysregulation^{73,74} than EpiMap (8.6%) and ABC model (4.4%) (Supplementary Figure 10c).
These results demonstrate the power SCENT achieved by accurately modeling association
between chromatin accessibility and gene expression at the single-cell resolution.

353 We hypothesized that putative causal variants by SCENT would likely modulate 354 chromatin accessibility (e.g., transcription factor binding affinity). If so, the intersection of the 355 SCENT enhancers and chromatin accessibility quantitative trait loci (caQTL) could further enrich 356 the causal GWAS variants^{75–78}, because these intersected enhancers should include genetic variants that directly change both chromatin accessibility and gene expression. To test this 357 358 hypothesis, we used single-cell ATAC-seq samples with genotype ($n_{donor} = 17$; arthritis-tissue 359 dataset) and performed caQTL mapping by leveraging allele-specific (AS) chromatin 360 accessibility (binomial test followed by meta-analysis across donors) or by combining AS with 361 inter-individual differences (RASQUAL⁷⁹). We then intersected the caQTL ATAC peaks with the 362 SCENT enhancers and calculated the causal variant enrichment within these intersected regions. 363 We observed higher enrichment within intersected regions with SCENT and caQTL than those 364 with SCENT alone. The enrichment increased as we used more stringent threshold for caQTL 365 peaks, reaching as high as 333-fold when compared with background *cis*-regions (Figure 3e). 366 Thus, SCENT efficiently prioritized causal GWAS variants in part by capturing regulatory regions

Sakaue et al

of which chromatin accessibility is perturbed by genetic variants and modulates gene expression.
 SCENT demonstrated a potential to further enrich causal variants by caQTLs if multimodal data
 has matched genotype data.

370

371 Defining mechanisms of GWAS loci by SCENT

372 We finally sought to use SCENT enhancer-gene links to define disease causal mechanisms. We 373 analyzed the fine-mapped variants from GWASs (FinnGen, UK Biobank and GWAS cohorts of 374 rheumatoid arthritis (RA)²⁶, inflammatory bowel disease²⁹ and type 1 diabetes (T1D)⁸⁰). SCENT 375 linked 4,124 putative causal variants (PIP>0.1) to their potential target genes across 1,143 traits 376 (Supplementary Table 4). These target genes were mostly close to the causal variant, with 377 20% of them being the closest gene to the causal variant (Supplementary Figure 12a and 12b; see Methods). However, 30.6% of the time SCENT linked causal variants to genes more than 378 379 300 kb away.

We first focus on autoimmune loci, given that our current SCENT tracks are largely 380 381 derived from immune cell types. We prioritized a single well fine-mapped variant rs72928038 (PIP > 0.3) at 6q15 locus in multiple autoimmune diseases (RA, T1D, atopic dermatitis and 382 383 hypothyroidism), within the T-cell-specific SCENT enhancer (T cells in Public PBMC and 384 Dogma-seg datasets; Figure 4a). This enhancer was linked to BACH2, which was also the 385 closest gene to this fine-mapped variant. Notably, base-editing in T cells has confirmed that this variant affects BACH2 expression⁸¹. Moreover, editing of this variant into CD8 T cells skewed 386 387 naive T cells toward effector T cell fates⁸¹.

388

Sakaue et al



- 390 Figure 4. SCENT defined causal variants and genes in complex trait GWAS.
- a. Rs72928038 at *BACH2* locus was prioritized by T-cell-specific SCENT enhancer-gene map,
 being for RA, T1D, Atopic dermatitis and hypothyroidism. The top four panels are GWAS regional

Sakaue et al

393 plots, with x-axis representing the position of each genetic variant. The color of the dots represent LD r² from the prioritized variant (highlighted by light blue stripe). ATAC-seq and 394 395 SCENT tracks represent aggregated ATAC-seq tracks (top) and SCENT peaks (bottom with 396 grey stripes) in each cell type (public PBMC dataset for immune cell types and arthritis-tissue dataset for fibroblast). An arrow head indicates the SCENT peak overlapping with fine-mapped 397 398 variant. b. Rs35944082 for RA and T1D was prioritized and connected to RBPJ by long-range 399 interaction from T-cell- and fibroblast- SCENT enhancer-gene map using inflamed synovium in 400 arthritis-tissue dataset. The top two panels are GWAS regional plots similarly to panel a. ATAC-401 seg and SCENT tracks are shown similarly to panel a, but using both public PBMC and arthritis-402 tissue datasets. c. Rs11031006 was prioritized and connected to FSHB for multiple 403 gynecological traits by using pituitary-derived single-cell multimodal dataset. The top four panels 404 are GWAS regional plots similarly to panel a. ATAC-seq and SCENT tracks are shown similarly 405 to panel a, and include tracks from pituitary dataset. There were no SCENT peaks in cell types 406 except for pituitary. d. ATAC-seq and SCENT tracks for IL10RA locus, where non-coding ClinVar 407 variants (grey dots) colocalized with T-cell SCENT track. e. ATAC-seq and SCENT tracks for 408 CXCR4 locus, where somatic mutation hotspot for leukemia colocalized with T-cell and myeloid-409 cell SCENT tracks.

Sakaue et al

410 Another locus for RA and T1D at 4p15.2 harbored 21 candidate variants, each with low 411 PIPs (< 0.14). SCENT prioritized a single variant rs35944082 in T cells and fibroblasts only within 412 the arthritis-tissue dataset from inflamed synovial tissue (Figure 4b). SCENT linked this variant 413 to RBPJ, which was the 3rd closest gene to this variant located 235kb away. This variant-gene 414 link was supported by a physical contact from promotor-capture Hi-C data in hematopoietic 415 cells⁸². *RBPJ* (recombination signal binding protein for immunoglobulin kappa J region) is a 416 transcription factor critical for NOTCH signaling, which has been implicated in RA tissue 417 inflammation through functional studies^{83,84}. *Rbpj* knockdown in mice resulted in abnormal T cell differentiation and disrupted regulatory T cell phenotype^{85,86}, consistent with a plausible role in 418 419 autoimmune diseases. Intriguingly, we observed no SCENT peaks in T cells from PBMC or blood 420 at this locus. This linkage was not present in EpiMap. ABC map prioritized another variant, 421 rs7441808 at this locus and linked it non-specifically to 16 genes including RBPJ, making it 422 difficult to define the true causal gene. These results underscored the importance of creating 423 enhancer-gene links using causal cell types, in this case cells from inflammatory tissues, in the 424 instances where links exist only in disease-relevant tissues.

We highlight another example of SCENT to build enhancer-gene maps from diseasecritical tissues. We examined the enhancer-gene map produced from single-cell pituitary data⁶² to assess 11p14.1 locus for multiple gynecological traits (endometriosis, menorrhagia, ovarian cyst and age at menopause). Our map connected rs11031006 to *FSHB* (follicle stimulating hormone subunit beta) (**Figure 4c**), which is specifically expressed in the pituitary^{70,87} and enables ovarian folliculogenesis to the antral follicle stage⁸⁸. Rare genetic variants within *FSHB*

Sakaue et al

cause autosomal recessive hypogonadotropic hypogonadism⁸⁹. However, multimodal data from
other tissues and bulk-based methods (ABC model and EpiMap) were unable to prioritize this
variant, since they missed the most disease-relevant tissue of pituitary.

434

435 Mendelian-disease variants and somatic mutations in cancer within SCENT enhancers

436 Having established the SCENT's utility in defining likely causal variants and genes in complex 437 diseases, we examined rare non-coding variants causing Mendelian diseases. Currently, causal 438 mutations and genes can only be identified in \sim 30–40% of patients with Mendelian diseases^{90–} 439 ⁹². Consequently, many variants in cases are annotated as variants of uncertain significance 440 (VUS). The VUS annotation is especially challenging for non-coding variants. We examined the 441 overlap of clinically reported non-benign non-coding variants by ClinVar⁹³ (400,300 variants in 442 total) within SCENT enhancers. The SCENT enhancers harbored 2.0 times ClinVar variants on 443 average than all the ATAC regions with the same genomic length across all the datasets 144 (Supplementary Figure 13). This density of ClinVar variants was 3.2 times and 12 times on 445 average larger than that in ENCODE cCREs and of all non-coding regions, respectively. We 446 defined 3,724 target genes for 33,618 non-coding ClinVar variants by SCENT in total 447 (Supplementary Table 5). As illustrative examples, we found 40 non-coding variants linked to LDLR gene causing familial hypercholesterolemia 193, 3 non-coding variants linked to IL10RA 448 449 causing autosomal recessive early-onset inflammatory bowel disease 28 (Figure 4d)⁹⁴, and an 450 intronic variant rs1591491477 linked to ATM gene causing hereditary cancer-predisposing 451 syndrome⁹³.

Sakaue et al

452 Finally, we used SCENT to connect non-coding somatic mutation hotspots to target genes. 453 Recently, somatic mutation analyses across the entire cancer genome revealed possible driver 454 non-coding events⁹⁵. Among 372 non-coding mutation hotspots in 19 cancer types, SCENT 455 enhancers included 193 cancer-mutation hotspot pairs (Supplementary Table 6). SCENT 456 enhancer-gene linkage successfully linked those hotspots to known driver genes (e.g., BACH2, 457 BCL6. BCR. CXCR4 (Figure 4e), and IRF8 in leukemia). In some instances, SCENT nominated different target genes for these mutation hotspots from those based on ABC model used in the 458 459 original study. For example, SCENT connected a somatic mutation hotspot in leukemia at 460 chr14:105568663-106851785 to IGHA1 (Immunoglobulin Heavy Constant Alpha 1), which might 461 be more biologically relevant than ADAM6 nominated by ABC model. These results implicate 462 broad applicability of SCENT for annotating all types of human variations in non-coding regions.

463

464 Augmenting SCENT enhancer-gene maps with more samples

While the recall for enhancer-gene maps defined by SCENT was lower than that by bulk-tissue-465 466 based methods, this might be a function of current limited sample sizes. We assessed if the addition of more cells into SCENT leads to the higher recall for enhancer-gene maps while 467 468 retaining the precision. By downsampling of our multimodal single cell dataset, we observed that the number of significant gene-peak pairs increased linearly to the number of cells per cell type 469 470 in a given dataset, suggesting that SCENT will be even better powered as the size of sc-471 multimodal datasets increases (Supplementary Figure 14). We considered the possibility that 472 enhancer-gene maps with greater numbers of cells might capture spurious associations; if this

Sakaue et al

473 was the case, we would expect more long-range associations, which are more likely to be false 474 positives with greater cell numbers. In contrast, shorter-range and longer-range associations 475 were both equivalently represented as we added cells, suggesting the robustness of our 476 discovery.

- 477
- 478
- 179 **Discussion**

480 In this study, we presented a novel statistical method, SCENT, to create a cell-type-specific 481 enhancer-gene map from single-cell multimodal data. Single-cell RNA-seg and ATAC-seg are 482 both sparse and have variable count distributions, which requires non-parametric bootstrapping 483 to connect chromatin accessibility with gene expression. The SCENT model demonstrated wellcontrolled type I error, outperforming commonly used statistical models which showed inflated 484 485 statistics. SCENT mapped enhancers that showed strikingly high enrichment for putative causal variants in eQTLs and GWASs and outperformed previous methods for single-cell multimodal 486 487 data (e.g., ArchR⁴⁹ and Signac⁵⁰). Despite using substantially lower number of samples (28 from 488 9 datasets in total), enhancers defined by SCENT had equivalent or even higher enrichment for 489 putative causal variants than bulk-tissue-based methods with more than 100 samples (e.g., 490 EpiMap and ABC model), by modeling single-cell level observations instead of obscuring them 491 into sample-level association.

As potential limitations, first, our enhancer-gene maps had relatively fewer enhancers (lower recall) compared to other resources (**Figure 2a**). However, downsampling experiments

Sakaue et al

494 showed a clear linear relationship between the number of cells and the number of significant 495 SCENT peak-gene links. It follows that SCENT applied to larger datasets from a diverse set of 496 tissues will further expand the current enhancer-gene map. In contrast, bulk-tissue-based 497 enhancer-gene map might have an upper limit of discovery by the number of samples generated by each consortium (e.g., ENCODE). Second, SCENT focuses on gene *cis*-regulatory 498 499 mechanisms to fine-map disease causal alleles, while there could be other causal mechanisms 500 that explain disease heritability, such as alleles that act through *trans*-regulatory effects, splicing 501 effects, or post-transcriptional effects⁹⁶.

502 We argue that the real utility of SCENT is that it enables the construction of disease-503 tissue-relevant enhancer-gene maps. Multimodal single cell data can be easily obtained from a 504 wide range of primary human tissues. Since these assays guery nuclear material, data can be obtained without disaggregating tissues and thus can be employed for assays that need intact 505 506 cells from tissue. Therefore, it is possible to build relevant tissue-specific enhancer-gene maps 507 that are necessary to understand the causal mechanisms of common diseases, rare diseases, 508 and somatic non-coding mutations in cancers. For example, understanding the FSHB locus in 509 gynecological traits specifically required a pituitary map, and RBPJ locus in RA specifically 510 required a synovial tissue map.

511 In summary, our method SCENT is a robust, versatile method to efficiently define causal 512 variants and genes in human diseases and will fill the gap in the current enhancer-gene map 513 built from genomic data in bulk tissues.

514

Sakaue et al

515 Data Availability

- 516 The publicly available datasets were downloaded via Gene Expression Ombibus (accession
- 517 codes: GSE140203, GSE156478, GSE178707, GSE193240, GSE178453) or web repository
- 518 (https://www.10xgenomics.com/resources/datasets?guery=&page=1&configure%5Bfacets%5D
- 519 <u>%5B0%5D=chemistryVersionAndThroughput&configure%5Bfacets%5D%5B1%5D=pipeline.ve</u>
- 520 <u>rsion&configure%5BhitsPerPage%5D=500&menu%5Bproducts.name%5D=Single%20Cell%2</u>
- 521 <u>0Multiome%20ATAC%20%2B%20Gene%20Expression</u>,
- 522 https://openproblems.bio/neurips_docs/data/dataset/). The raw data for arthritis-tissue dataset
- 523 (single-cell multimodal RNA/ATAC-seq and single-cell ATAC-seq) will be publicly available
- 524 before the acceptance of this manuscript.
- 525

526 **Code Availability**

- 527 The computational scripts related to this manuscript are available at 528 https://github.com/immunogenomics/SCENT.
- 529

530 Methods

531 Data and sample in arthritis-tissue dataset

This study was performed in accordance with protocols approved by the Brigham and Women's Hospital and the Hospital for Special Surgery institutional review boards. Synovial tissue from patients with RA and OA were collected from synovectomy or arthroplasty procedures followed by cryopreservation as previously described⁹⁷. RA samples with high levels of lymphocyte

Sakaue et al

536 infiltration (as scored by a pathologist on histologic sections) were identified as "inflamed" and 537 used for downstream analysis. Next, cryopreserved synovial tissue fragments were dissociated 538 by a mechanical and enzymatic digestion⁹⁷, followed by flow sorting to enrich for live synovial 539 cells. For each tissue sample, the viable cells were isolated and lysed to extract and load 540 approximately 10,000 nuclei according to manufacturer protocol (10X Genomics). Joint sc-RNA-541 and sc-ATAC-seq libraries were prepared using the 10x Genomics Single Cell Multiome ATAC 542 + Gene Expression kit according to manufacturer's instructions. Libraries were sequenced with 543 paired-end 150-bp reads on an Illumina Novaseg to a target depth of 30,000 read pairs per nuclei both for mRNA and ATAC libraries. Demultiplexed scRNA-seg fastg files were inputted 544 545 into the Cell Ranger ARC pipeline (version 2.0.0) from 10x Genomics to generate barcoded 546 count matrix of gene expression. For ATAC-seq, we trimmed adaptor and primer sequences and mapped the trimmed reads to the hg38 genome by BWA-MEM with default parameters. To 547 548 deduplicate reads from PCR amplification bias within a cell while keeping reads originating from 549 the same positions but from different cells, we used in-house scripts (manuscript in preparation).

550

551 Uniform processing of single-cell multimodal datasets

In addition to our arthritis-tissue multimodal dataset, we downloaded all publicly available multimodal RNA-seq/ATAC-seq datasets from adult human tissues ($n_{dataset}$ = 9, as of April 2022). We processed these downloaded count matrices of gene expression and ATAC data. Briefly, we applied QC to both the nuclear RNA data and the ATAC data based on RNA counts, ATAC fragments, nucleosome signal, and TSS enrichment (**Supplementary Table 7**). We only kept

Sakaue et al

557 cells that had passed QC in both RNA-seq and ATAC-seq. Then to identify open chromatin 558 regions (peaks), we used macs2 to call open chromatin peaks using post-QC ATAC-seg data. 559 We thus obtained count matrices of gene expression and ATAC peaks with corresponding cell 560 barcodes. Gene expression counts were normalized using the NormalizeData function (Seurat⁹⁸), scaled using the ScaleData function (Seurat), and batch corrected using Harmony⁹⁹. 561 562 We visualized the cells in two low-dimensional embeddings with UMAP by using 20 batch-563 corrected principal components from these normalized gene expression matrices (Figure 1c). 564 When original cell labels are provided by the authors, we used those labels to obtain broad cell 565 type categories. When they are not available, we performed reference-query mapping by Seurat 566 and PBMC reference object to define broad cell type labels. ATAC peak matrix was binarized to 567 have 1 if a count is > 0 and 0 otherwise.

568

569 SCENT method

570 We defined *cis*-peaks as any peaks whose center is within the window +/-500 kb from a given 571 gene body. We modeled the association between peak's binarized accessibility and the target 572 gene's expression with Poisson distribution:

573 $E_i \sim Poisson(\lambda_i)$

574
$$log(\lambda_i) = \beta_0 + \beta_{peak} X_{peak} + \beta_{\% mito} X_{\% mito} + \beta_{nUMI} X_{nUMI} + \beta_{batch} X_{batch} \quad (Equation 1)$$

where E_i is the observed expression count of *i*th gene, and λ_i is the expected count under Poisson distribution. β_{peak} indicates the effect of chromatin accessibility of a peak on *i* th gene expression. $\beta_{\% mito}$, β_{nUMI} , and β_{batch} each represents the effect of covariates, percentage of

Sakaue et al

578 mitochondrial reads per cell as a mesure of cell quality, the number of UMIs in the cell, and the 579 batch, respectively. To empirically assess error and significance of β_{peak} for each peak-gene 580 combination, we used bootstrapping procedures. In brief, we resampled cells with replacement in each bootstrapping procedure and re-estimated β'_{peak} within those resampled cells. We 581 repeated this procedure N times, where we adaptively increased N (i.e., the total number of 582 bootstrapping) from at least 100 and up to 50,000, depending on the significance of β_{peak} (as 583 described next) in each chunk of bootstrapping trials to reduce the computational burden. After 584 585 *N* times of bootstrapping, we assessed the distribution of N β'_{peak} s against null hypothesis $(\beta'_{peak} = 0)$ to derive the significance of β_{peak} (i.e., two-sided bootstrapping-based *P* value for 586 587 this peak-gene combination by counting the instances where the statistics are equal or more extreme than the null hypothesis of $\beta'_{peak} = 0$; **Supplementary Figure 2**). 588

To avoid spurious associations from rare ATAC peak and rare gene expression, we QCed cis-peak-gene pairs we test so that both peak and gene should have been expressed in at least 5% of the cells we analyze. We finally defined a set of significant peak-gene pairs for each cell type based on bootstrapping-based *P* values and FDR correction for multiple testing (Benjamini & Hochberg correction).

594 When we tested the calibration of statistics from SCENT or other regression strategies 595 (**Supplementary Figure 1**), we used null dataset where we randomly permuted cell labels in the 596 ATAC-seq and ran the regression model we tested.

597

598 ArchR peak2gene and Signac LinkPeaks method

Sakaue et al

We analyzed arthritis-tissue dataset with ArchR⁴⁹ and Signac⁵⁰ for single-cell multimodal data, 599 300 which both have a function to define peak-gene linkages. In brief, ArchR takes multimodal data 301 and creates low-overlapping aggregates of single cells based on *k*-nearest neighbor graph. Then 302 it correlates peak accessibility with gene expression by Pearson correlation of aggregated and 303 log2-normalized peak count and gene count. Signac computes the Pearson correlation 304 coefficient r (corSparse function in R) for each gene and for each peak within 500kb of the gene 305 TSS. Signac then compares the observed correlation coefficient with an expected correlation 306 coefficient for each peak given the GC content, accessibility, and length of the peak. Signac 307 defines *P* value for each gene-peak links from the z score based on this comparison. We ran 308 both methods on arthritis-tissue dataset with default parameters. We output statistics for all 309 peak-gene pairs we tested without any cut-off for correlation r or P values. We used FDR in the 510 output from ArchR software, or computed FDR using P values in the output from Signac software 311 by Benjamini & Hochberg correction. We defined significant peak-gene linkages as those with 312 FDR < 0.10, and used varying correlation r to assess the precision and recall in the causal variant 313 enrichment analysis (see later sections in Method).

314

315 *Replication across datasets*

516 Since we have the same immune-related cell types across different multimodal datasets, we 517 evaluated the concordance of enhancer-gene map in a discovery dataset (arthritis-tissue 518 dataset) when compared with other replication datasets including immune-related cell types 519 (Public PBMC, NeurIPS, SHARE-seq and NEAT-seq datasets). To this end, we used most

Sakaue et al

320	stringent FDR threshold for defining an enhancer-gene map in arthritis-tissue dataset (FDR <
321	1%). We then used more lenient threshold for defining an enhancer-gene map in replication
322	datasets (FDR < 10%), which is a similar strategy used in assessing replication in GWAS. For
323	each cell type and for each replication dataset, we took the intersection of enhancer-gene links
324	defined as significant in both datasets. We assessed the directional concordance (i.e.,
325	concordance of the sign of β_{peak}) and the Pearson's correlation r of β_{peak} between the
326	discovery and the replication for these peak-gene pairs. For the largest replication dataset of
327	Public PBMC, we performed the same analysis for enhancer-gene map from ArchR and Signac
328	software.

329

530 Conservation score analysis

531 To compare the evolutional conservation across species between our annotated peaks and the 332 other peaks, we used phastCons⁶⁶ score. We downloaded the phastCons score for multiple 333 of alignments 99 vertebrate from genomes 534 https://hgdownload.cse.ucsc.edu/goldenpath/hg19/phastCons100way/. We lifted them over to 335 GRCh38 by LiftOver software. We used SCENT results for arthritis-tissue, Public PBMC and 536 NeurIPS for conservation score analysis as representative datasets with the largest numbers of 337 cells. Because each gene should have variable functional importance and conservation, we 338 assessed each gene separately. For each gene, we took (1) an annotation of interest for the gene and (2) all *cis*-non-coding regions (< 500kb from a gene), and computed the mean 539 340 phastCons score of each of two sets of the peaks. As annotations to be tested, we used a. exonic

Sakaue et al

regions of the gene, b. SCENT peaks for the gene, and c. all ATAC peaks in cis-regions from the gene (< 500 kb). Then, we took the difference between two mean differences (Δ phastCons score), and computed the mean differences across all the genes (mean Δ phastCons score) as follows.

545 mean
$$\Delta$$
 phastCons score = $\frac{1}{n_{gene}} \sum_{gene} \overline{(phastCons_{g,in_annot} - phastCons_{g,non_coding})}$

By bootstrapping the genes, we calculated the 95% CI of the mean Δ phastCons score. If this metric is positive, that indicates that the annotated regions are more conserved than noncoding regions.

We also calculated similar ∆ phastCons score by comparing the SCENT peaks with
 TSS-distance-matched non-SCENT peaks in each dataset.

351 mean Δ phastCons score

$$352 \qquad \qquad = \frac{1}{n_{gene}} \sum_{gene} \overline{(phastCons}_{g,peak_in_SCENT} - \overline{phastCons}_{g,peak_non_SCENT_matched})$$

By bootstrapping the genes, we again calculated the 95% CI of the mean Δ phastCons score. If this metric is positive, that indicates that SCENT peaks are more conserved than TSSdistance-matched non-SCENT peaks.

- 356
- 357 Construction of a set of TSS-matched non-SCENT peaks

358 To assess the effect of TSS distance when comparing SCENT peaks with non-SCENT peaks,

359 we matched each one of the SCENT peak-gene pairs to one non-SCENT peak-gene pair, where

the peak had the most similar TSS distance to the same gene among all the ATAC peaks in *cis*

in each of the dataset. We confirmed that the resulting TSS-distance-matched non-SCENT

Sakaue et al

- peak-gene pairs demonstrated the similar distributions of TSS distance when compared with the
 SCENT peak-gene pairs (Supplementary Figure 6b).
- 364

365 Gene's constraint and the number of significant SCENT peaks for a gene

We sought to investigate the relationship between the number of significant SCENT peaks for 366 367 each gene and the gene's evolutionary constraint. We used pLI and LOEUF as metrics for the 368 gene's loss-of-function intolerance within human population. We downloaded both pLI and 369 LOEUF scores from gnomAD browser (https://gnomad.broadinstitute.org/downloads). We 370 inverse-normal transformed the raw number of significant SCENT peaks for each gene, since 371 the raw number of significant SCENT peaks for each gene is skewed toward zero 372 (Supplementary Figure 5a). We performed linear regression between the normalized number 373 of significant SCENT peaks and pLI or LOEUF score with accounting for gene length, which 374 could be potential confounding factor for pLI and LOEUF^{67,68}.

375

376 Validation with CRISPR-Flow FISH results

To validate our SCENT enhancer-gene links, we used published CRISPR-Flow FISH experiments as potential ground-truth positive enhancer element-gene links and negative enhancer element-gene links. We downloaded the experimental results from the **Supplementary Table 5** of original publication³⁹. We used "Perturbation Target" as candidate enhancer elements. We defined 283 positive enhancer element-gene links when they are "TRUE" for "Regulated" column (i.e., the element-gene pair is significant and the effect size is negative)

Sakaue et al

and 5,472 negative enhancer element-gene links when they are "FALSE" for "Regulated" column.
We lifted them over to GRCh38 and obtained final sets of 278 positive links and 5,470 negative
links.

We used two most powered datasets, arthritis-tissue and Public PBMC datasets. For each dataset, we used "bedtools intersect" to categorize SCENT peak-gene links and non-SCENT ATAC peak-gene pairs into either CRISPR-positive or CRISPR-negative groups, based on whether these peaks overlapped with positive or negative CRISPR-Flow FISH links for the same gene (**Supplementary Table 3**). We finally performed two-sided Fisher's exact test to assess the enrichment of CRISPR-positive links within SCENT peak-gene links in each dataset.

392

393 Cell-type-specific SCENT tracks and aggregated SCENT tracks

For cell types with more than 5,000 cells across datasets, we concatenated SCENT peak-gene linkages across all the datasets to create cell-type-specific SCENT tracks. We collected a set of SCENT peak-gene linkages for the same cell type and used "bedtools merge" function (for each gene) to obtain a union of SCENT peaks for each gene. Similarly, we created aggregated SCENT tracks across all the cell types and all datasets. We collected all sets of SCENT peakgene linkages and used "bedtools merge" function (for each gene) to obtain a union of SCENT peaks for each gene across all the cell types and all datasets.

701

702 Causal variant enrichment analysis using eQTLs

Sakaue et al

703 We defined a causal enrichment for eQTL within SCENT enhancers and other annotations by 704 using statistically fine-mapped variant-gene combinations from GTEx. We used publicly available statistics analyzed by CAVIAR software²⁰, and selected variants with PIP > 0.2 as 705 706 putatively causal (fine-mapped) variants for primary analyses. For the primary enrichment 707 analysis, we aggregated fine-mapped variants from all the 49 tissues. For cell-type-specific 708 SCENT enrichment analysis (Supplementary Figure 9d), we used fine-mapped variants from 709 each tissue separately. We intersected these putatively causal variants with our annotation 710 (SCENT peaks, ArchR peaks or Signac peaks). We then retained any variants which the linking 711 method (SCENT, ArchR, Signac, and Cicero) connected to the same gene as GTEx phenotype 712 gene.

713
$$Enrichment_{gene_{i}} = \frac{\# causal_var_in_annot_{gene_{i}}}{\# causal_var_{gene_{i}}} / \sum common_var_in_annot_{gene_{i}}} / \sum common_var_in_cis_{gene_{i}}$$

714

715
$$Overall_Enrichment = \frac{1}{n} \sum_{i=1}^{n} Enrichment_{gene_i}$$

For each gene *i* (expression phenotype), we divided the number of putatively causal variants within an annotation normalized by the number of common variants within an annotation by the number of all causal variants for gene *i* normalized by the number of all common variants within cis-region from for gene *i*. To calculate common variants within annotation or within locus, we used 1000 Genomes Project genotype. We selected any variants with minor allele frequency > 1% in European population as a set of common variants to be intersected with each annotation. To derive *Overall_Enrichment* score, we took the mean across all the genes.

723	To have further insights into precision and recall and compare against ArchR peak2gene
724	and Signac LinkPeaks functions, we varied the threshold for defining a set of significant peak-
725	gene linkages in each software (i.e., FDR in SCENT {0.50, 0.30, 0.20, 0.10, 0.05, 0.02},
726	Peason's correlation r {any, 0, 0.1, 0.3, 0.5, 0.7} in ArchR, and correlation socre {any, 0, 0.05,
727	0.1, 0.15} in Signac). We used the same myeloid cells in the arthritis-tissue dataset and a set of
728	eQTL fine-mapped variants in GTEx blood tissue for this benchmark across all three methods.
729	We then used each set of peak-gene linkages to re-calculate causal variant enrichment
730	Overall_Enrichment score (Figure 3b).
731	We also assessed the impact of PIP threshold in defining a set of statistically fine-mapped
732	variants on the causal variant enrichment analysis. To do so, we re-defined the set of putative
733	causal variants with more stringent PIP thresholds (PIP > 0.5 and PIP > 0.7), and re-computed
734	the calculate causal variant enrichment Overall_Enrichment score.
735	
736	Cicero co-accessibility analyses
737	To benchmark our SCENT using single-cell multimodal ATAC/RNA-seq against a published
738	method using single-cell unimodal ATAC-seq alone, we ran Cicero ⁵¹ for the same dataset of
739	myeloid cells in the arthritis-tissue dataset as benchmarked in the SCENT, ArchR and Signac.
740	We only used the peak by cell matrix from the ATAC-seq side of the arthritis-tissue dataset and
741	ran "run_cicero" function with default parameters to obtain Cicero co-accessibility scores. We
742	only retained peak-peak co-accessibility as potential enhancer-gene connection when one of the
743	co-accessible peaks is a promoter of a gene (defined by the peak's distance to the TSS < 1kb);

Sakaue et al

we treated them as putative enhancer-gene (promoter) linkage. We used the co-accessibility
scores {any, 0, 0.1, 0.3, 0.4, 0.5, 0.7} for assessing the recall-precision tradeoffs as described in
the previous section.

747

748 Peak-gene linkage using Poisson regression alone

As other benchmarking for assessing the effect of the components of SCENT on the causal variant enrichment, we also created peak-gene linkage using the Poisson regression but without non-parametric bootstrapping for the same dataset of myeloid cells in the arthritis-tissue dataset. We used the nominal *P* values for the term X_{peak} from the Poisson regression (*Equation* (1)) to perform FDR correction to obtain significant peak-gene pairs using the Poisson regression alone. We then used the FDR thresholds {0.30, 0.20, 0.10, 0.05, 0.02, 0.01} for assessing the recall-precision tradeoffs as described in the previous section.

756

757 GWAS fine-mapping results

We used GWAS fine-mapping results in FinnGen release 6^{71} upon registration and publicly available GWAS fine-mapping results in UK Biobank⁷² (https://www.finucanelab.org/data). For FinnGen traits, we downloaded all the fine-mapping results by SuSIE software²² and systematically selected any traits with case count > 1,000. We then selected non-coding finemapped loci which did not include any non-synonymous or splicing variants with PIP > 0.5. We thus analyzed 1,046 traits and 5,753 loci in total after QC. For UK Biobank, we analyzed the fine-mapping results by SuSIE software for all 94 traits including binary and quantitative traits.

Sakaue et al

765	Since the genomic coordinates for the UK Biobank fine-mapping results were hg19, we lifted
766	them over to GRCh38 by using LiftOVer software. We again selected non-coding fine-mapped
767	loci which did not include any non-synonymous or splicing variants with PIP > 0.5. We thus
768	analyzed 7,274 loci in total after QC.
769	We analyzed three additional autoimmune GWAS fine-mapping results for RA ²⁶ , T1D ⁸⁰ ,
770	and IBD ²⁹ , given our special interest in immune-mediated traits. We similarly selected non-
771	coding fine-mapped loci which did not include any non-synonymous or splicing variants with PIP
772	> 0.5, and lifted the results over to GRCh38 by using LiftOVer software. We defined 117 loci for

- 773 RA, 77 loci for T1D and 86 loci for IBD.
- 774
- 775 Causal variant enrichment analysis using GWASs

We defined a causal enrichment for GWAS within SCENT enhancers and other annotations by using statistically fine-mapped variants from FinnGen⁷¹ and UK Biobank⁷² which we described in the previous section. We selected variants with PIP > 0.2 as putatively causal variants for primary analyses.

780
$$Enrichment_{trait_{i}} = \frac{\# causal_{var_{in_{annot_{trait_{i}}}}}{\# causal_{var_{trait_{i}}}} \sum common_{var_{in_{annot_{trait_{i}}}}}{\frac{\# causal_{var_{trait_{i}}}}{\sum common_{var_{across_{loci_{trait_{i}}}}}}}$$

781

782
$$Overall_Enrichment = \frac{1}{n} \sum_{i=1}^{n} Enrichment_{trait_i}$$

For each trait *i*, we divided the number of putatively causal variants within an annotation (across
all loci for trait *i*) normalized by the number of common variants within an annotation by the

Sakaue et al

number of all causal variants for trait *i* normalized by the number of all common variants within all significant loci analyzed for the trait *i*. To calculate common variants within annotation or within locus, we again used 1000 Genomes Project variants with minor allele frequency > 1% in European population. To derive *Overall_Enrichment* score, we took the mean across all the traits.

For each trait *i* and putative causal gene pair, we calculated the distance between the TSS of the gene and the most likely causal variant which had the largest PIP when multiple variants were nominated for a single gene by SCENT (**Supplementary Figure 12a**). For each putative causal gene for the trait *i*, we also sorted all the genes based on the distance between the gene's TSS and the most likely causal variant (from the smallest to the largest). We then obtained the rank of the putative causal gene from SCENT among the sorted gene list to see how often the SCENT gene is the closest gene from the most likely causal variant.

797

798 Comparison with bulk-tissue-based regulatory annotation and enhancer-gene maps

799 downloaded from We per-group EpiMap enhancer-gene links 300 https://personal.broadinstitute.org/cboix/epimap/links/pergroup/. lifted We the genomic 301 coordinates to GRCh38 by using LiftOver software. When we assessed aggregated EpiMap 302 enhancer-gene links across all the 31 tissue-groups, we used "bedtools merge" function for each 303 gene to create a union of all enhancer-gene links (Figure 3c and d). For tissue-specific 304 enrichment analyses, we analyzed the 31 group-specific tracks separately (Supplementary 305 Figure 10a and 10b). To benchmark the precision and recall, we used EpiMap correlation scores

Sakaue et al

to define variable sets of enhancer-gene links from EpiMap based on the threshold of EpiMap
 correlation score.

We 308 downloaded ABC predictions in 131 cell types and tissues from 309 ftp://ftp.broadinstitute.org/outgoing/lincRNA/ABC/AllPredictions.AvgHiC.ABC0.015.minus150.F 310 orABCPaperV3.txt.gz. We lifted the genomic coordinates to GRCh38 by using LiftOver software. 311 When we assessed aggregated ABC enhancer-gene links across all the groups, we used 312 "bedtools merge" function for each gene to create a union of all enhancer-gene links across 131 313 cell types (Figure 3c and d). For cell-type-specific analyses, we aggregated cell lines or cell 314 types to be corresponding with our cell types and analyzed each of these tracks separately (B 315 cell, T cell, Myeloid cells, and fibroblasts; **Supplementary Figure 10a** and **10b**). To benchmark 316 the precision and recall, we used ABC scores to define variable sets of enhancer-gene links 317 from ABC model based on the threshold of ABC score.

318 To assess precision and recall and compare against bulk-tissue based methods (i.e., 319 EpiMap and ABC model), we used sets of significant peak-gene linkages in each method with 320 varying thresholds (i.e., FDR in SCENT {0.5, 0.3, 0.2, 0.1, 0.05, 0.02}, EpiMap correlation score 321 {0, 0.4, 0.8, 0.9} in EpiMap, and ABC score {0, 0.05, 0.1, 0.2} for ABC model). We then used 322 each set of peak-gene linkages to re-calculate causal variant enrichment for GWAS (Figure 3d). 323 We also assessed the impact of PIP threshold in defining a set of statistically fine-mapped 324 variants on the causal variant enrichment analysis. To do so, we re-defined the set of putative 325 causal variants with more stringent PIP thresholds (PIP > 0.5 and PIP > 0.7), and re-computed 326 the calculate causal variant enrichment *Overall_Enrichment* score.

Sakaue et al

327

328 caQTL analysis using scATAC-seq samples with genotype

329 We generated independent arthritis-tissue dataset with single-cell unimodal ATAC-seg data with 330 genotype (n = 17, manuscript in preparation) to define chromatin accessibility QTLs (caQTLs). We used two methods, binomial test and RASQUAL. Briefly, we genotyped donors by using 331 332 Illumina Multi-Ethnic Genotyping Array. We performed quality control of genotype by sample call rate > 0.99, variant call rate > 0.99, minor allele frequency > 0.01, and P_{HWE} > 1.0×10⁻⁶. We 333 334 performed haplotype phasing with SHAPEIT2 software¹⁰⁰ and performed whole-genome imputation by using minimac3 software¹⁰¹ with a reference panel of 1000 Genomes Project 335 336 phase 3^{102} . After imputation, we selected variants with imputation Rsq > 0.7 as post-imputation 337 QC. We next created a merged bam file of ATAC-seq for each donor and each cell type by 338 aggregating all the reads. Using the imputed genotype for each donor and aggregated bam files 339 for each donor and cell type, we applied WASP¹⁰³ to correct any bias in read mapping toward 340 reference alleles to accurately quantify allelic imbalance. We thus created a bias-corrected bam 341 files for each donor and cell type.

For binomial tests, we ran ASEReadCounter module in GATK software¹⁰⁴ using the biascorrected bam files as input to quantify allelic imbalance in heterozygous sites with read count > 4 within ATAC peak counts. We first performed one-sided binomial tests in each donor, and meta-analyzed the statistics across donors by Fisher's method if multiple donors shared the same heterozygous site. For RASQUAL, we created a VCF file containing both genotype dosage and allelic imbalance from ASEReadCounter. We quantified the read coverage for each peak

Sakaue et al

and for each donor by "bedtools coverage" function. We created a peak by donor matrix with 348 349 read coverage. We QCed samples with log(total mapped fragments) fewer than mean - 2SD 350 across samples in each cell type. We QCed peaks so that at least two individuals have any 351 fragments for the peak. We then ran RASQUAL software with the inter-individual differences in ATAC peak counts (in a peak by donor matrix) and intra-individual allelic imbalance (in VCF), 352 353 with accounting for chromatin accessibility PCs (the first N components whose explained 354 variances are greater than those from permutation result), 3 genotype PCs, sample site and sex 355 as covariates. RASQUAL output chi-squared statistics and P values. We computed FDR from 356 these raw P values by Benjamini & Hochberg correction on local multiple test burden (i.e., the 357 number of *cis*-SNPs in the region). To correct for genome-wide multiple testing, we ran the 358 RASQUAL with random permutation, where the relationship between sample labels and the 359 count matrix was broken. Thus, we derived q values for each candidate caQTL.

We finally intersected these peaks with significant caQTL effect in each significance threshold with SCENT peaks and assessed causal variants enrichment within these peaks for GWAS as explained in the previous sections.

363

364 *ClinVar analysis*

We downloaded the latest clinically reported variant list registered at ClinVar from https://ftp.ncbi.nlm.nih.gov/pub/clinvar/vcf_GRCh38/clinvar.vcf.gz. We then screened the variants to exclude (1) exonic variants and (2) variants categorized as "benign". We defined the

Sakaue et al

- 368 ClinVar variant density as the number of the non-coding and non-benign variants within each 369 annotation x 1,000 divided by the total length (bp) of each annotation.
- 370
- 371 Somatic mutation analysis

We used a list of somatic mutation hotspot in Supplementary Table 2-20 of the original publication⁹⁵. We lifted the genomic coordinates to GRCh38 by using LifOver software. We then intersected the non-coding somatic mutation hotspots with our cell-type-specific SCENT peaks. We compared the intersected elements' target genes by SCENT with the "Annotate_Gene" column from the original publication.

377

378 Downsampling experiments

To evaluate the effect of cell numbers on the statistical power in detecting significant SCENT enhancer-gene linkages, we performed downsampling experiments in fibroblast (the most abundant cell type in arthritis-tissue dataset, $n_{cell} = 9,905$). We randomly samples cells ($n_{cell} =$ 500, 1000, 2500, 5000, and 7500). We then applied SCENT to each of the subset groups of cells and defined significant peak-gene links with FDR < 10%. We counted the number of significant peak-gene links in each of the subset groups of cells, and annotated peaks based on the distance to the TSS to the target gene.

386

387 **References**

Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A.,
 Flicek, P., Manolio, T., Hindorff, L., et al. (2014). The NHGRI GWAS Catalog, a curated

- resource of SNP-trait associations. Nucleic Acids Res 42, D1001-6.
- 391 10.1093/nar/gkt1229.
- Visscher, P.M., Wray, N.R., Zhang, Q., Sklar, P., McCarthy, M.I., Brown, M.A., and
 Yang, J. (2017). 10 Years of GWAS Discovery: Biology, Function, and Translation. Am J
 Hum Genet *101*, 5–22. 10.1016/J.AJHG.2017.06.005.
- Buniello, A., Macarthur, J.A.L., Cerezo, M., Harris, L.W., Hayhurst, J., Malangone, C.,
 McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019). The NHGRI-EBI GWAS
 Catalog of published genome-wide association studies, targeted arrays and summary
 statistics 2019. Nucleic Acids Res *47*, D1005–D1012. 10.1093/NAR/GKY1120.
- Claussnitzer, M., Cho, J.H., Collins, R., Cox, N.J., Dermitzakis, E.T., Hurles, M.E.,
 Kathiresan, S., Kenny, E.E., Lindgren, C.M., MacArthur, D.G., et al. (2020). A brief
 history of human disease genetics. Nature 2020 577:7789 577, 179–189.
 10.1038/s41586-019-1879-7.
- Plenge, R.M., Scolnick, E.M., and Altshuler, D. (2013). Validating therapeutic targets
 through human genetics. Nature Reviews Drug Discovery 2013 12:8 *12*, 581–594.
 10.1038/nrd4051.
- Shendure, J., Findlay, G.M., and Snyder, M.W. (2019). Genomic Medicine–Progress,
 Pitfalls, and Promise. Cell *177*, 45–57. 10.1016/J.CELL.2019.02.003.
- Schaid, D.J., Chen, W., and Larson, N.B. (2018). From genome-wide associations to
 candidate causal variants by statistical fine-mapping. Nature Reviews Genetics 2018
 19:8 *19*, 491–504. 10.1038/s41576-018-0016-z.
- 311 8. Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, H.,
- Reynolds, A.P., Sandstrom, R., Qu, H., Brody, J., et al. (2012). Systematic localization of
 common disease-associated variation in regulatory DNA. Science (1979) 337, 1190–
 1195. 10.1126/SCIENCE.1222794/SUPPL FILE/MAURANO.SM.PDF.
- 9. Edwards, S.L., Beesley, J., French, J.D., and Dunning, M. (2013). Beyond GWASs:
 916 illuminating the dark road from association to function. Am J Hum Genet *93*, 779–797.
 917 10.1016/J.AJHG.2013.10.012.
- Trynka, G., Sandor, C., Han, B., Xu, H., Stranger, B.E., Liu, X.S., and Raychaudhuri, S.
 (2013). Chromatin marks identify critical cell types for fine mapping complex trait
- yariants. Nat Genet *45*, 124–130. 10.1038/ng.2504.

- 321 11. Sanyal, A., Lajoie, B.R., Jain, G., and Dekker, J. (2012). The long-range interaction
 322 landscape of gene promoters. Nature 2012 489:7414 489, 109–113.
 323 40.4020/s at we 14270
- 923 10.1038/nature11279.
- Smemo, S., Tena, J.J., Kim, K.H., Gamazon, E.R., Sakabe, N.J., Gómez-Marín, C.,
 Aneas, I., Credidio, F.L., Sobreira, D.R., Wasserman, N.F., et al. (2014). Obesity associated variants within FTO form long-range functional connections with IRX3. Nature
 2014 507:7492 507, 371–375. 10.1038/nature13138.
- Won, H., de La Torre-Ubieta, L., Stein, J.L., Parikshak, N.N., Huang, J., Opland, C.K.,
 Gandal, M.J., Sutton, G.J., Hormozdiari, F., Lu, D., et al. (2016). Chromosome
 conformation elucidates regulatory relationships in developing human brain. Nature 2016
 538:7626 538. 523–527. 10.1038/nature19847.
- Strober, B.J., Elorbany, R., Rhodes, K., Krishnan, N., Tayeb, K., Battle, A., and Gilad, Y.
 (2019). Dynamic genetic regulation of gene expression during cellular differentiation.
 Science *364*, 1287–1290. 10.1126/SCIENCE.AAW0040.
- Scuomo, A.S.E., Seaton, D.D., McCarthy, D.J., Martinez, I., Bonder, M.J., GarciaBernardo, J., Amatya, S., Madrigal, P., Isaacson, A., Buettner, F., et al. (2020). Singlecell RNA-sequencing of differentiating iPS cells reveals dynamic genetic effects on gene
 expression. Nature Communications 2020 11:1 *11*, 1–14. 10.1038/s41467-020-14457-z.
- 239 16. Zhernakova, D. v., Deelen, P., Vermaat, M., van Iterson, M., van Galen, M., Arindrarto,
 240 W., Van't Hof, P., Mei, H., van Dijk, F., Westra, H.J., et al. (2017). Identification of
 241 context-dependent expression quantitative trait loci in whole blood. Nat Genet *49*, 139–
 242 145. 10.1038/NG.3737.
- Nathan, A., Asgari, S., Ishigaki, K., Valencia, C., Amariuta, T., Luo, Y., Beynor, J.I.,
 Baglaenko, Y., Suliman, S., Price, A.L., et al. (2022). Single-cell eQTL models reveal
 dynamic T cell state dependence of disease loci. Nature 2022 606:7912 606, 120–128.
 10.1038/s41586-022-04713-1.
- Wakefield, J. (2007). A Bayesian Measure of the Probability of False Discovery in
 Genetic Epidemiology Studies. Am J Hum Genet *81*, 208. 10.1086/519024.
- 19. Maller, J.B., McVean, G., Byrnes, J., Vukcevic, D., Palin, K., Su, Z., Howson, J.M.M.,
- Auton, A., Myers, S., Morris, A., et al. (2012). Bayesian refinement of association signals
- 951 for 14 loci in 3 common diseases. Nat Genet *44*, 1294–1301. 10.1038/NG.2435.

- Hormozdiari, F., Kostem, E., Kang, E.Y., Pasaniuc, B., and Eskin, E. (2014). Identifying
 causal variants at loci with multiple signals of association. Genetics *198*, 497–508.
 10.1534/GENETICS.114.167908.
- Benner, C., Spencer, C.C.A., Havulinna, A.S., Salomaa, V., Ripatti, S., and Pirinen, M.
 (2016). FINEMAP: efficient variable selection using summary data from genome-wide
- 357 association studies. Bioinformatics 32, 1493–1501.
- 358 10.1093/BIOINFORMATICS/BTW018.
- Wang, G., Sarkar, A., Carbonetto, P., and Stephens, M. (2020). A simple new approach
 to variable selection in regression, with application to genetic fine mapping. J R Stat Soc
 Series B Stat Methodol *82*, 1273–1300. 10.1111/RSSB.12388.
- Weissbrod, O., Hormozdiari, F., Benner, C., Cui, R., Ulirsch, J., Gazal, S., Schoech,
 A.P., van de Geijn, B., Reshef, Y., Márquez-Luna, C., et al. (2020). Functionally informed
 fine-mapping and polygenic localization of complex trait heritability. Nature Genetics
 2020 52:12 52. 1355–1363. 10.1038/s41588-020-00735-5.
- Wojcik, G.L., Graff, M., Nishimura, K.K., Tao, R., Haessler, J., Gignoux, C.R., Highland,
 H.M., Patel, Y.M., Sorokin, E.P., Avery, C.L., et al. (2019). Genetic analyses of diverse
 populations improves discovery for complex traits. Nature 2019 570:7762 570, 514–518.
 10.1038/s41586-019-1310-4.
- 25. Chen, M.H., Raffield, L.M., Mousas, A., Sakaue, S., Huffman, J.E., Moscati, A., Trivedi,
 B., Jiang, T., Akbari, P., Vuckovic, D., et al. (2020). Trans-ethnic and Ancestry-Specific
 Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. Cell *182*, 11981213.e14. 10.1016/J.CELL.2020.06.045.
- 374 26. Ishigaki, K., Sakaue, S., Terao, C., Luo, Y., Sonehara, K., Yamaguchi, K., Amariuta, T.,
 375 Too, C.L., Laufer, V.A., Scott, I.C., et al. (2021). Trans-ancestry genome-wide
- association study identifies novel genetic mechanisms in rheumatoid arthritis. medRxiv
 2021.12.01.21267132. 10.1101/2021.12.01.21267132.
- 378 27. Kichaev, G., and Pasaniuc, B. (2015). Leveraging Functional-Annotation Data in Trans379 ethnic Fine-Mapping Studies. Am J Hum Genet 97, 260–271.
- 980 10.1016/J.AJHG.2015.06.007.
- 28. Kanai, M., Ulirsch, J.C., Karjalainen, J., Kurki, M., Karczewski, K.J., Fauman, E., Wang,
 28. Q.S., Jacobs, H., Aguet, F., Ardlie, K.G., et al. (2021). Insights from complex trait fine-

Sakaue et al

mapping across diverse populations. medRxiv, 2021.09.03.21262975.

984 10.1101/2021.09.03.21262975.

- 985 29. Huang, H., Fang, M., Jostins, L., Umićević Mirkov, M., Boucher, G., Anderson, C.A.,
- Andersen, V., Cleynen, I., Cortes, A., Crins, F., et al. (2017). Fine-mapping inflammatory
- bowel disease loci to single-variant resolution. Nature *547*, 173–178.

988 10.1038/NATURE22969.

- 30. Farh, K.K.H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W.J., Beik, S., Shoresh,
 N., Whitton, H., Ryan, R.J.H., Shishkin, A.A., et al. (2014). Genetic and epigenetic fine
 mapping of causal autoimmune disease variants. Nature 2014 518:7539 *518*, 337–343.
 10.1038/nature13835.
- 31. Mahajan, A., Taliun, D., Thurner, M., Robertson, N.R., Torres, J.M., Rayner, N.W.,
- Payne, A.J., Steinthorsdottir, V., Scott, R.A., Grarup, N., et al. (2018). Fine-mapping type
 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific
 epigenome maps. Nature Genetics 2018 50:11 *50*, 1505–1513. 10.1038/s41588-0180241-6.
- 32. Kichaev, G., Yang, W.Y., Lindstrom, S., Hormozdiari, F., Eskin, E., Price, A.L., Kraft, P.,
 and Pasaniuc, B. (2014). Integrating functional data to prioritize causal variants in
 statistical fine-mapping studies. PLoS Genet *10*. 10.1371/JOURNAL.PGEN.1004722.
- 33. Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M.,
 Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015).
 Integrative analysis of 111 reference human epigenomes. Nature 2015 518:7539 *518*,
 317–330. 10.1038/nature14248.
- 34. Chen, L., Ge, B., Casale, F.P., Vasquez, L., Kwan, T., Garrido-Martín, D., Watt, S., Yan,
 Y., Kundu, K., Ecker, S., et al. (2016). Genetic Drivers of Epigenetic and Transcriptional
 Variation in Human Immune Cells. Cell *167*, 1398-1414.e24. 10.1016/j.cell.2016.10.026.
- 35. Dunham, I., Kundaje, A., Aldred, S.F., Collins, P.J., Davis, C.A., Doyle, F., Epstein, C.B.,
 Frietze, S., Harrow, J., Kaul, R., et al. (2012). An integrated encyclopedia of DNA
 elements in the human genome. Nature *489*, 57–74. 10.1038/NATURE11247.
- 36. Ernst, J., Kheradpour, P., Mikkelsen, T.S., Shoresh, N., Ward, L.D., Epstein, C.B.,
- 212 Zhang, X., Wang, L., Issner, R., Coyne, M., et al. (2011). Mapping and analysis of
- 013 chromatin state dynamics in nine human cell types. Nature 2011 473:7345 473, 43–49.
- 014 10.1038/nature09906.

- 37. Boix, C.A., James, B.T., Park, Y.P., Meuleman, W., and Kellis, M. (2021). Regulatory
 genomic circuitry of human disease loci by integrative epigenomics. Nature 2021
 590:7845 590, 300–307. 10.1038/s41586-020-03145-z.
- 38. Fulco, C.P., Nasser, J., Jones, T.R., Munson, G., Bergman, D.T., Subramanian, V.,
 Grossman, S.R., Anyoha, R., Doughty, B.R., Patwardhan, T.A., et al. (2019). Activity-byContact model of enhancer-promoter regulation from thousands of CRISPR
- D21 perturbations. Nat Genet *51*, 1664. 10.1038/S41588-019-0538-0.
- 39. Nasser, J., Bergman, D.T., Fulco, C.P., Guckelberger, P., Doughty, B.R., Patwardhan,
 T.A., Jones, T.R., Nguyen, T.H., Ulirsch, J.C., Lekschas, F., et al. (2021). Genome-wide
 enhancer maps link risk variants to disease genes. Nature 2021 593:7858 593, 238–243.
 10.1038/s41586-021-03446-x.
- 40. Gazal, S., Weissbrod, O., Hormozdiari, F., Dey, K.K., Nasser, J., Jagadeesh, K.A.,
 Weiner, D.J., Shi, H., Fulco, C.P., O'Connor, L.J., et al. (2022). Combining SNP-to-gene
 linking strategies to identify disease genes and assess disease omnigenicity. Nat Genet
 54, 827–836. 10.1038/S41588-022-01087-Y.
- Pickar-Oliver, A., and Gersbach, C.A. (2019). The next generation of CRISPR–Cas
 technologies and applications. Nature Reviews Molecular Cell Biology 2019 20:8 *20*,
 490–507. 10.1038/s41580-019-0131-5.
- Anzalone, A. v., Koblan, L.W., and Liu, D.R. (2020). Genome editing with CRISPR–Cas
 nucleases, base editors, transposases and prime editors. Nature Biotechnology 2020
 38:7 38, 824–844. 10.1038/s41587-020-0561-9.
- Baglaenko, Y., Macfarlane, D., Marson, A., Nigrovic, P.A., and Raychaudhuri, S. (2021).
 Genome editing to define the function of risk loci and variants in rheumatic disease.
- D38Nature Reviews Rheumatology 2021 17:8 17, 462–474. 10.1038/s41584-021-00637-8.
- 339 44. Cao, J., Cusanovich, D.A., Ramani, V., Aghamirzaie, D., Pliner, H.A., Hill, A.J., Daza,
- R.M., McFaline-Figueroa, J.L., Packer, J.S., Christiansen, L., et al. (2018). Joint profiling
 of chromatin accessibility and gene expression in thousands of single cells. Science
 (1979) 361, 1380–1385.
- 043 10.1126/SCIENCE.AAU0730/SUPPL_FILE/AAU0730_TABLESS1_S13.XLSX.
- Chen, S., Lake, B.B., and Zhang, K. (2019). High-throughput sequencing of the
 transcriptome and chromatin accessibility in the same cell. Nature Biotechnology 2019
- 046 37:12 37, 1452–1457. 10.1038/s41587-019-0290-0.

-)47 46. Ma, S., Zhang, B., LaFave, L.M., Earl, A.S., Chiang, Z., Hu, Y., Ding, J., Brack, A.,)48 Kartha, V.K., Tay, T., et al. (2020). Chromatin Potential Identified by Shared Single-Cell)49 Profiling of RNA and Chromatin. Cell 183, 1103-1116.e20. 10.1016/J.CELL.2020.09.056.)50 47. Allaway, K.C., Gabitto, M.I., Wapinski, O., Saldi, G., Wang, C.Y., Bandler, R.C., Wu,)51 S.J., Bonneau, R., and Fishell, G. (2021). Genetic and epigenetic coordination of cortical)52 interneuron development. Nature 2021 597:7878 597, 693-697. 10.1038/s41586-021-)53 03933-1.)54 Trevino, A.E., Müller, F., Andersen, J., Sundaram, L., Kathiria, A., Shcherbina, A., Farh, 48.)55 K., Chang, H.Y., Pasca, A.M., Kundaje, A., et al. (2021). Chromatin and gene-regulatory)56 dynamics of the developing human cerebral cortex at single-cell resolution. Cell 184,)57 5053-5069.e23. 10.1016/J.CELL.2021.07.039.)58 49. Granja, J.M., Corces, M.R., Pierce, S.E., Bagdatli, S.T., Choudhry, H., Chang, H.Y., and)59 Greenleaf, W.J. (2021). ArchR is a scalable software package for integrative single-cell 060 chromatin accessibility analysis. Nature Genetics 2021 53:3 53. 403-411.
- 061 10.1038/s41588-021-00790-6.
- 50. Stuart, T., Srivastava, A., Madad, S., Lareau, C.A., and Satija, R. (2021). Single-cell
 chromatin state analysis with Signac. Nature Methods 2021 18:11 *18*, 1333–1341.
 10.1038/s41592-021-01282-5.
- 51. Pliner, H.A., Packer, J.S., McFaline-Figueroa, J.L., Cusanovich, D.A., Daza, R.M.,
 Aghamirzaie, D., Srivatsan, S., Qiu, X., Jackson, D., Minkina, A., et al. (2018). Cicero
 Predicts cis-Regulatory DNA Interactions from Single-Cell Chromatin Accessibility Data.
 Mol Cell *71*, 858-871.e8. 10.1016/J.MOLCEL.2018.06.044.
- 52. Efron, B., and Tibshirani, R.J. (1994). An Introduction to the Bootstrap. An Introduction to
 the Bootstrap. 10.1201/9780429246593.
- 53. Lähnemann, D., Köster, J., Szczurek, E., McCarthy, D.J., Hicks, S.C., Robinson, M.D.,
 Vallejos, C.A., Campbell, K.R., Beerenwinkel, N., Mahfouz, A., et al. (2020). Eleven
 grand challenges in single-cell data science. Genome Biology 2020 21:1 *21*, 1–35.
 10.1186/S13059-020-1926-6.
- 54. Sarkar, A., and Stephens, M. (2021). Separating measurement and expression models
 clarifies confusion in single-cell RNA sequencing analysis. Nature Genetics 2021 53:6
 53, 770–777. 10.1038/s41588-021-00873-4.

- 55. Chen, H., Lareau, C., Andreani, T., Vinyard, M.E., Garcia, S.P., Clement, K., AndradeNavarro, M.A., Buenrostro, J.D., and Pinello, L. (2019). Assessment of computational
 methods for the analysis of single-cell ATAC-seq data. Genome Biol *20*, 1–25.
 10.1186/S13059-019-1854-5/FIGURES/7.
- 56. Granja, J.M., Klemm, S., McGinnis, L.M., Kathiria, A.S., Mezger, A., Corces, M.R.,
 Parks, B., Gars, E., Liedtke, M., Zheng, G.X.Y., et al. (2019). Single-cell multiomic
 analysis identifies regulatory programs in mixed-phenotype acute leukemia. Nature
 Biotechnology 2019 37:12 37, 1458–1465. 10.1038/s41587-019-0332-7.
- 57. Townes, F.W., Hicks, S.C., Aryee, M.J., and Irizarry, R.A. (2019). Feature selection and
 dimension reduction for single-cell RNA-Seq based on a multinomial model. Genome
 Biol 20, 1–16. 10.1186/S13059-019-1861-6/FIGURES/5.
- 58. Luecken, M.D., Burkhardt, D.B., Cannoodt, R., Lance, C., Agrawal, A., Aliee, H., Chen,
 A.T., Deconinck, L., Detweiler, A.M., Granados, A., et al. (2021). A sandbox for
 prediction and integration of DNA, RNA, and proteins in single cells. Proceedings of the
 Neural Information Processing Systems Track on Datasets and Benchmarks *1*.
- 59. Mimitou, E.P., Lareau, C.A., Chen, K.Y., Zorzetto-Fernandes, A.L., Hao, Y., Takeshima,
 Y., Luo, W., Huang, T.S., Yeung, B.Z., Papalexi, E., et al. (2021). Scalable, multimodal
 profiling of chromatin accessibility, gene expression and protein levels in single cells. Nat
 Biotechnol 39, 1246–1258. 10.1038/S41587-021-00927-2.
- Chen, A.F., Parks, B., Kathiria, A.S., Ober-Reynolds, B., Goronzy, J.J., and Greenleaf,
 W.J. (2022). NEAT-seq: simultaneous profiling of intra-nuclear proteins, chromatin
 accessibility and gene expression in single cells. Nature Methods 2022 19:5 *19*, 547–
 553. 10.1038/s41592-022-01461-y.
- Meijer, M., Agirre, E., Kabbe, M., van Tuijn, C.A., Heskol, A., Zheng, C., Mendanha
 Falcão, A., Bartosovic, M., Kirby, L., Calini, D., et al. (2022). Epigenomic priming of
 immune genes implicates oligodendroglia in multiple sclerosis susceptibility. Neuron *110*,
 1193-1210.e13. 10.1016/J.NEURON.2021.12.034.
- 105 62. Zhang, Z., Zamojski, M., Smith, G.R., Willis, T.L., Yianni, V., Mendelev, N., Pincas, H.,
 106 Seenarine, N., Amper, M.A.S., Vasoya, M., et al. (2022). Single nucleus transcriptome
 107 and chromatin accessibility of postmortem human pituitaries reveal diverse stem cell
 108 regulatory mechanisms. Cell Rep *38*. 10.1016/J.CELREP.2022.110467.

Sakaue et al

109 63. Abascal, F., Acosta, R., Addleman, N.J., Adrian, J., Afzal, V., Aken, B., Akiyama, J.A., 110 Jammal, O. al, Amrhein, H., Anderson, S.M., et al. (2020). Expanded encyclopaedias of 111 DNA elements in the human and mouse genomes. Nature 2020 583:7818 583, 699-710. 112 10.1038/s41586-020-2493-4. 113 Westra, H.J., and Franke, L. (2014). From genome to function by studying eQTLs. 64. 114 Biochim Biophys Acta 1842, 1896–1902. 10.1016/J.BBADIS.2014.04.024. 115 65. Hujoel, M.L.A., Gazal, S., Hormozdiari, F., van de Geijn, B., and Price, A.L. (2019). 116 Disease Heritability Enrichment of Regulatory Elements Is Concentrated in Elements 117 with Ancient Sequence Age and Conserved Function across Species. Am J Hum Genet 118 104, 611–624. 10.1016/j.ajhg.2019.02.008. 119 66. Siepel, A., Beierano, G., Pedersen, J.S., Hinrichs, A.S., Hou, M., Rosenbloom, K., 120 Clawson, H., Spieth, J., Hillier, L.D.W., Richards, S., et al. (2005). Evolutionarily 121 conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res 15, 122 1034-1050. 10.1101/GR.3715005. 123 67. Lek, M., Karczewski, K.J., Minikel, E. v., Samocha, K.E., Banks, E., Fennell, T., 124 O'Donnell-Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B., et al. (2016). Analysis of 125 protein-coding genetic variation in 60,706 humans. Nature 536, 285–291. 126 10.1038/nature19057. 127 Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins, 68. 128 R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint 129 spectrum quantified from variation in 141,456 humans. Nature 581, 434–443. 130 10.1038/s41586-020-2308-7. 131 69. Wang, X., and Goldstein, D.B. (2020). Enhancer Domains Predict Gene Pathogenicity 132 and Inform Gene Discovery in Complex Disease. The American Journal of Human 133 Genetics 106. 215-233. 10.1016/J.AJHG.2020.01.012. Aguet, F., Barbeira, A.N., Bonazzola, R., Brown, A., Castel, S.E., Jo, B., Kasela, S., Kim-134 70. Hellmuth, S., Liang, Y., Oliva, M., et al. (2020). The GTEx Consortium atlas of genetic 135 136 regulatory effects across human tissues. Science 369, 1318. 137 10.1126/SCIENCE.AAZ1776. 138 71. Kurki, M.I., Karjalainen, J., Palta, P., Sipilä, T.P., Kristiansson, K., Donner, K., Reeve, 139 M.P., Laivuori, H., Aavikko, M., Kaunisto, M.A., et al. (2022). FinnGen: Unique genetic

Sakaue et al

- 140 insights from combining isolated population and national health register data. medRxiv, 141 2022.03.03.22271360. 10.1101/2022.03.03.22271360.
- 142 72. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motver, A.,
- 143 Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with 144 deep phenotyping and genomic data. Nature 562, 203-209. 10.1038/s41586-018-0579-Z.
- 145

146 73. Dey, K.K., Gazal, S., van de Geijn, B., Kim, S.S., Nasser, J., Engreitz, J.M.,

- 147 Correspondence, A.L.P., and Price, A.L. (2022). SNP-to-gene linking strategies reveal 148 contributions of enhancer-related and candidate master-regulator genes to autoimmune 149 disease. Cell Genomics 2, 100145. 10.1016/j.xgen.2022.100145.
- 150 74. Freund, M.K., Burch, K.S., Shi, H., Mancuso, N., Kichaev, G., Garske, K.M., Pan, D.Z., 151 Miao, Z., Mohlke, K.L., Laakso, M., et al. (2018). Phenotype-Specific Enrichment of 152 Mendelian Disorder Genes near GWAS Regions across 62 Complex Traits. The 153 American Journal of Human Genetics 103, 535–552, 10,1016/J.AJHG,2018,08,017.
- 154 75. Gate, R.E., Cheng, C.S., Aiden, A.P., Siba, A., Tabaka, M., Lituiev, D., Machol, I., 155 Gordon, M.G., Subramaniam, M., Shamim, M., et al. (2018). Genetic determinants of co-156 accessible chromatin regions in activated T cells across humans. Nature Genetics 2018 157 50:8 50, 1140-1150. 10.1038/s41588-018-0156-2.
- 158 Khetan, S., Kursawe, R., Youn, A., Lawlor, N., Jillette, A., Marguez, E.J., Ucar, D., and 76. 159 Stitzel, M.L. (2018). Type 2 Diabetes-Associated Genetic Variants Regulate Chromatin 160 Accessibility in Human Islets. Diabetes 67, 2466–2477. 10.2337/DB18-0393.
- 161 Alasoo, K., Rodrigues, J., Mukhopadhyay, S., Knights, A.J., Mann, A.L., Kundu, K., Hale, 77. 162 C., Dougan, G., and Gaffney, D.J. (2018). Shared genetic effects on chromatin and gene 163 expression indicate a role for enhancer priming in immune response. Nat Genet 50, 424. 164 10.1038/S41588-018-0046-7.
- 165 78. Currin, K.W., Erdos, M.R., Narisu, N., Rai, V., Vadlamudi, S., Perrin, H.J., Idol, J.R., Yan, T., Albanus, R.D.O., Broadaway, K.A., et al. (2021). Genetic effects on liver chromatin 166 167 accessibility identify disease regulatory variants. Am J Hum Genet 108, 1169–1189. 168 10.1016/J.AJHG.2021.05.001.
- 169 Kumasaka, N., Knights, A.J., and Gaffney, D.J. (2015). Fine-mapping cellular QTLs with 79. 170 RASQUAL and ATAC-seq. Nature Genetics 2015 48:2 48, 206-213. 10.1038/ng.3467.

- Chiou, J., Geusz, R.J., Okino, M.L., Han, J.Y., Miller, M., Melton, R., Beebe, E.,
 Benaglio, P., Huang, S., Korgaonkar, K., et al. (2021). Interpreting type 1 diabetes risk
 with genetics and single-cell epigenomics. Nature 2021 594:7863 594, 398–402.
 10.1038/s41586-021-03552-w.
 Mouri, K., Guo, M.H., de Boer, C.G., Lissner, M.M., Harten, I.A., Newby, G.A., DeBerg,
- H.A., Platt, W.F., Gentili, M., Liu, D.R., et al. (2022). Prioritization of autoimmune
 disease-associated genetic variants that perturb regulatory element activity in T cells.
 Nature Genetics 2022 54:5 54, 603–612. 10.1038/s41588-022-01056-5.
- 179 82. Javierre, B.M., Sewitz, S., Cairns, J., Wingett, S.W., Várnai, C., Thiecke, M.J., Freire180 Pritchett, P., Spivakov, M., Fraser, P., Burren, O.S., et al. (2016). Lineage-Specific
 181 Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene
 182 Promoters. Cell *167*, 1369-1384.e19. 10.1016/J.CELL.2016.09.037.
- 183 83. Radtke, F., Fasnacht, N., and MacDonald, H.R. (2010). Notch signaling in the immune
 184 system. Immunity *32*, 14–27. 10.1016/J.IMMUNI.2010.01.004.
- 185 84. Wei, K., Korsunsky, I., Marshall, J.L., Gao, A., Watts, G.F.M., Major, T., Croft, A.P.,
 186 Watts, J., Blazar, P.E., Lange, J.K., et al. (2020). Notch signalling drives synovial
 187 fibroblast identity and arthritis pathology. Nature *582*, 259–264. 10.1038/S41586-020188 2222-Z.
- 189 85. Delacher, M., Schmidl, C., Herzig, Y., Breloer, M., Hartmann, W., Brunk, F., Kägebein,
 190 D., Träger, U., Hofer, A.C., Bittner, S., et al. (2019). Rbpj expression in regulatory T cells
 191 is critical for restraining TH2 responses. Nature Communications 2019 10:1 *10*, 1–20.
 192 10.1038/s41467-019-09276-w.
- 193 86. Blake, J.A., Baldarelli, R., Kadin, J.A., Richardson, J.E., Smith, C.L., and Bult, C.J.
- 194 (2021). Mouse Genome Database (MGD): Knowledgebase for mouse-human
 195 comparative biology. Nucleic Acids Res *49*, D981. 10.1093/NAR/GKAA1083.
- 196 87. Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A.,
 197 Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Tissue-based map of
- the human proteome. Science (1979) 347.
- 199 10.1126/SCIENCE.1260419/SUPPL_FILE/1260419_UHLEN.SM.PDF.
- 200 88. Hillier, S.G. (2001). Gonadotropic control of ovarian follicular growth and development.
- 201 Mol Cell Endocrinol *179*, 39–46. 10.1016/S0303-7207(01)00469-5.

202	89.	Rubinstein, W.S., Maglott, D.R., Lee, J.M., Kattman, B.L., Malheiro, A.J., Ovetsky, M.,
203		Hem, V., Gorelenkov, V., Song, G., Wallin, C., et al. (2013). The NIH genetic testing
204		registry: a new, centralized database of genetic tests to enable access to comprehensive
205		information and improve transparency. Nucleic Acids Res 41, D925–D935.
206		10.1093/NAR/GKS1173.
207	90.	Retterer, K., Juusola, J., Cho, M.T., Vitazka, P., Millan, F., Gibellini, F., Vertino-Bell, A.,
208		Smaoui, N., Neidich, J., Monaghan, K.G., et al. (2016). Clinical application of whole-
209		exome sequencing across clinical indications. Genet Med 18, 696–704.
210		10.1038/GIM.2015.148.
211	91.	Adams, D.R., and Eng, C.M. (2018). Next-Generation Sequencing to Diagnose
212		Suspected Genetic Disorders. N Engl J Med 379, 1353–1362.
213		10.1056/NEJMRA1711801.
214	92.	Srivastava, S., Love-Nichols, J.A., Dies, K.A., Ledbetter, D.H., Martin, C.L., Chung,
215		W.K., Firth, H. v., Frazier, T., Hansen, R.L., Prock, L., et al. (2019). Meta-analysis and
216		multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic
217		test for individuals with neurodevelopmental disorders. Genet Med 21, 2413–2421.
218		10.1038/S41436-019-0554-6.
219	93.	Landrum, M.J., Lee, J.M., Benson, M., Brown, G.R., Chao, C., Chitipiralla, S., Gu, B.,
220		Hart, J., Hoffman, D., Jang, W., et al. (2018). ClinVar: improving access to variant
221		interpretations and supporting evidence. Nucleic Acids Res 46, D1062–D1067.
222		10.1093/NAR/GKX1153.
223	94.	Glocker, EO., Kotlarz, D., Boztug, K., Gertz, E.M., Schäffer, A.A., Noyan, F., Perro, M.,
224		Diestelhorst, J., Allroth, A., Murugan, D., et al. (2009). Inflammatory Bowel Disease and
225		Mutations Affecting the Interleukin-10 Receptor. New England Journal of Medicine 361,
226		2033–2045.
227		10.1056/NEJMOA0907206/SUPPL_FILE/NEJM_GLOCKER_2033SA1.PDF.
228	95.	Dietlein, F., Wang, A.B., Fagre, C., Tang, A., Besselink, N.J.M., Cuppen, E., Li, C.,
229		Sunyaev, S.R., Neal, J.T., and van Allen, E.M. (2022). Genome-wide analysis of somatic
230		noncoding mutation patterns in cancer. Science (1979) 376.
231		10.1126/SCIENCE.ABG5601/SUPPL_FILE/SCIENCE.ABG5601_MDAR_REPRODUCIB
232		ILITY_CHECKLIST.PDF.

- 233 96. Connally, N., Nazeen, S., Lee, D., Shi, H., Stamatoyannopoulos, J., Chun, S., Cotsapas,
 234 C., Cassa, C.A., and Sunyaev, S. (2022). The missing link between genetic association
 235 and regulatory function. medRxiv, 2021.06.08.21258515.
 236 10.1101/2021.06.08.21258515.
- 97. Donlin, L.T., Rao, D.A., Wei, K., Slowikowski, K., McGeachy, M.J., Turner, J.D., Meednu,
 N., Mizoguchi, F., Gutierrez-Arcelus, M., Lieb, D.J., et al. (2018). Methods for highdimensonal analysis of cells dissociated from cyropreserved synovial tissue. Arthritis
 Res Ther *20*, 1–15. 10.1186/S13075-018-1631-Y/FIGURES/6.
- Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., Hao, Y.,
 Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of SingleCell Data. Cell *177*, 1888-1902.e21. 10.1016/J.CELL.2019.05.031.
- Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y.,
 Brenner, M., Loh, P. ru, and Raychaudhuri, S. (2019). Fast, sensitive and accurate
 integration of single-cell data with Harmony. Nature Methods 2019 16:12 *16*, 1289–1296.
 10.1038/s41592-019-0619-0.
- 248 100. Delaneau, O., Marchini, J., and Zagury, J.F. (2012). A linear complexity phasing method
 249 for thousands of genomes. Nat Methods *9*, 179–181. 10.1038/nmeth.1785.
- 250 101. Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, S.I., Chew,
 251 E.Y., Levy, S., McGue, M., et al. (2016). Next-generation genotype imputation service
 252 and methods. Nature Genetics 2016 48:10 *48*, 1284–1287. 10.1038/ng.3656.
- 253 102. Gibbs, R.A., Boerwinkle, E., Doddapaneni, H., Han, Y., Korchina, V., Kovar, C., Lee, S.,
 254 Muzny, D., Reid, J.G., Zhu, Y., et al. (2015). A global reference for human genetic
 255 variation. Nature *526*, 68–74. 10.1038/nature15393.
- van de Geijn, B., Mcvicker, G., Gilad, Y., and Pritchard, J.K. (2015). WASP: allelespecific software for robust molecular quantitative trait locus discovery. Nat Methods *12*,
 1061–1063. 10.1038/NMETH.3582.
- 259 104. van der Auwera, G., O'Connor, B., and Safari, an O.M.Company. (2020). Genomics in
 260 the Cloud.
- 261
- 262
- 263 Acknowledgments

Sakaue et al

We would like to sincerely thank participants of this study who provided tissue samples. We 264 265 thank Anika Gupta, Joyce Kang and Kaitlyn Lagattuta for their comments and helpful discussion 266 on the manuscript. This work is supported in part by funding from the National Institutes of Health 267 (R01AR063759, U01HG012009, UC2AR081023). S.S. was in part supported by the Uehara 268 Memorial Foundation and The Osamu Hayaishi Memorial Scholarship. K.Wei is supported by a 269 Burroughs Wellcome Fund Career Awards for Medical Scientists, a Doris Duke Charitable 270 Foundation Clinical Scientist Development Award, and a Rheumatology Research Foundation 271 Innovative Research Award. We would like to thank the Brigham and Women's Hospital Center 272 for Cellular Profiling Single Cell Mulitomics Core for experimental design and protocol 273 optimization.

274

275 Author Contributions

276 S.S. and S.R. conceived the work and wrote the manuscript with critical input from co-authors.

277 S.S. and K. Weinand analyzed the arthritis-tissue dataset and S.S. analyzed publicly available

278 datasets with help and guidance from K.K.D., K.J., M.K., A.M., A.L.P., and S.R. G.F.M.W., Z.Z.,

279 M.B.B., L.T.D., and K.Wei provided samples and generated the arthritis-tissue dataset. S.I.

refactored the SCENT software implementation as an R package.

281

282 **Competing Financial Interests**

283 We declare no conflict of interest for this study. S.R. is a founder for Mestag, Inc, a scientific 284 advisor for Rheos, Jannsen, and Pfizer, and serves as a consultant for Sanofi and Abbvie.